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Abstract 
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Background: The MMSE is commonly used as a screening instrument for 
cognitive impairment in stroke services.  However, recent research has shown 
that it has poor diagnostic validity for use in this patient population.  The 
purpose of this study was to examine the validity of the ACE-R as an alternative 
screening measure for use in stroke. 
Objectives:  The first objective was to determine whether the ACE-R is more 
accurate than the MMSE at detecting overall cognitive impairment in stroke.  
The second objective was to determine the accuracy of the ACE-R subscales 
for detecting impairments in specific cognitive domains. 
Methods:  This study had a cross-sectional design.  40 patients were recruited 
from an inpatient stroke service.  They were administered the ACE-R (which 
includes the MMSE), and a battery of more detailed neuropsychological tests, 
which served as the ‘gold standard’ for classification of impairment.  The 
diagnostic validity of the ACE-R and MMSE was determined by ROC analysis.   
Results: Both the MMSE and the ACE-R were found to have inadequate 
diagnostic validity for the detection of overall cognitive impairment.  No cut-
scores scores could be identified which yielded test sensitivity of >80% and 
specificity of >60%.  Levels of specificity were particularly poor.  The ACE-R 
subscales showed a similar pattern of performance, indicating inadequate 
validity for the detection of impairment in specific areas of cognitive functioning. 
Conclusions:  There was no support for the use of the MMSE or the ACE-R 
when screening for cognitive impairment in acute stroke.  Further research 
should focus on the identification of an alternative measure. 
 
Key words: Stroke, cognitive impairment, screening, sensitivity, specificity. 
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 The ACE-R stroke validation project was initially the concept of two Clinical 
Psychologists affiliated with Nottingham University Hospitals NHS Trust Clinical 
Psychology service; Professor Nadina Lincoln and Dr Vicki Hacker.  The 
Trainee (author) contributed to the project design and independently carried out 
the literature review and application for ethical approval.   The recruitment of 
patients was conducted by the Trainee, assisted by an Assistant Psychologist 
(Daniel Stark) and an MSc student (Kimberly Fletcher).  The collection of patient 
demographic information, and the administration and scoring of the ACE-R 
screening tests was carried out by the Assistant Psychologist and MSc student.  
The Trainee was responsible for the administration, scoring and interpretation of 
the full neuropsychological test batteries.  Clinical reports on each patient were 
written for the Stroke Service by the Trainee, under the supervision of Dr Vicki 
Hacker, Clinical Psychologist.   Data entry was completed by the Trainee, 
assisted by the MSc student.  Data analysis was independently carried out by 
the Trainee. 
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Introduction 
 
Cognitive impairment is common following stroke, and is present in 
approximately 70% of patients in the acute stages of recovery [1].  The nature 
and severity of cognitive impairment varies according to the location of the 
stroke, but may include problems with memory, perception, language, attention, 
or executive functioning [1,2,3].  Over and above the physical impairments 
caused by stroke, cognitive difficulties impact on a person’s ability to carry out 
tasks of everyday living and affect their ability to live independently [4,5].  As 
such, there is a clear need to accurately detect the presence of cognitive 
impairment in acute stroke, in order to inform prognosis, rehabilitation planning, 
and provision of care.  Accordingly, the National Clinical Guidelines for Stroke, 
recommends that all stroke patients should be assessed for the presence of 
cognitive impairment [6].  (See appendix 1.1 for further information regarding 
cognitive impairment in stroke.) 
 
Detailed neuropsychological testing is time consuming and costly for services, 
and tiring for acutely unwell patients.  Thus, brief cognitive screening measures 
are required to identify those patients with impairment and to highlight problem 
areas for further assessment.  A screening measure should have high levels of 
sensitivity (able to correctly identify people with problems) and high levels of 
specificity (able to correctly identify people without problems).  Where screening 
pre-empts full testing, it may be better to compromise specificity for sensitivity to 
ensure that most of those people with problems are correctly identified.  It is 
recommended in the literature that screening measures have a sensitivity of 80-
0809, RES, Research Project, UofL: 06060035, UofN: 4059149, page 9 of 145 
90% and a specificity of greater than 60% [7].  In addition to their psychometric 
properties, screening measures should also be brief, easy to administer by staff 
not trained in neuropsychological assessment, and suitable for bedside 
(hospital) administration.  (See appendix 1.2 for further information on the 
principles of cognitive screening.) 
 
The Mini Mental State Examination (MMSE) [8] is the most widely used of all 
cognitive screening measures, in stroke and other clinical services [9].  Like 
most screening measures it was originally developed to screen for dementia in 
community geriatric populations, consisting mainly of patients with Alzheimer’s 
type dementia.  It has been found to have high levels of diagnostic validity for 
this purpose, and is especially accurate at detecting moderate-severe 
impairment [10].  However, recent research has indicated that, in acute stroke 
populations, the MMSE has poor diagnostic validity for the detection of cognitive 
impairment [1,11,].  The most recent paper reported that, in stroke, the MMSE 
has a sensitivity of 34%, a specificity of 70%, and Area Under the Curve (AUC) 
= 0.67, p=0.13) [1].  The diagnostic validity is likely to be so poor in stroke due 
to this population comprising of patients with both focal deficits as well as 
dementia syndromes.   The MMSE only measures a limited range of cognition, 
focussing on verbal functions and omitting any measure of executive 
functioning.  As such, patients suffering predominantly from impairments in 
executive or perceptual functioning are missed by the MMSE [1].  (See 
appendix 1.3.1 for further information on the MMSE.) 
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Other commonly used screening tests are the Cambridge Cognitive 
Examination (CAMCOG) [12], and a shortened version, the Rotterdam-
Cambridge Cognitive Examination (R-CAMCOG) [13].  These were also 
designed for use in community dementia populations.  They offer more 
comprehensive assessment compared to the MMSE and both have been 
shown to have superior diagnostic validity for the detection of dementia 
syndromes, including vascular dementia [13,14,15].  However, their utility for 
the detection of cognitive impairment in an acute stroke population (patients 
with focal impairments and patients with vascular dementia) has not been 
examined.  Their potential for this purpose may be limited due to the omission 
of a measure of executive functioning.  Furthermore, the CAMCOG/ CAMCOG-
R are likely to be impractical for use in acute stroke as they require specialised 
test equipment.  (See appendix 1.3.2 and appendix 1.3.3 for further information 
on the CAMCOG and R-CAMCOG.) 
 
The Addenbrooke’s Cognitive Examination-Revised (ACE-R) [16], successor to 
the Addenbrooke’s Cognitive Examination (ACE) [17], is an alternative option.   
Like the MMSE and the CAMCOG, the ACE-R was also designed for use in 
community dementia populations, but its design and psychometric properties 
suggest it may be more suitable for use in acute stroke.  The ACE-R covers a 
more comprehensive range of cognitive impairment than both the MMSE and 
CAMCOG, including a measure of executive functioning.  A further advantage 
of the ACE-R is that it provides normative data for five subscales, allowing 
accurate analysis of the pattern of cognitive impairment.  Unlike the CAMCOG 
tests, the ACE-R does not require any materials other than the test sheet to 
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administer.  Validity studies have indicated that the ACE-R has increased 
sensitivity and specificity for the detection of dementia, compared to the MMSE, 
although there has been some debate over the ideal cut-off score [16, 18].  One 
study has also given early indications that the ACE-R is a valid measure for the 
detection of cognitive impairment in brain injury [19].  (See appendix 1.3.4 and 
appendix 1.3.5 for further information on the ACE and ACE-R.) 
 
The diagnostic validity of the ACE/ACE-R for the detection of cognitive 
impairment in acute stroke patients has not yet been examined, and this was 
the aim of the current study.  There were two main research objectives.  The 
first objective was to determine whether the ACE-R is more accurate than the 
MMSE at detecting the presence of overall cognitive impairment.   The second 
objective was to determine the accuracy of the ACE-R in detecting impairments 
in specific areas of functioning (memory, attention, perception and executive 
functioning).  In relation to the first objective, it is hypothesised that the ACE-R 
will be more accurate at detecting the presence of cognitive impairment 
compared to the MMSE in stroke.  This prediction is made on the basis of the 
results found in dementia populations [17], and the assumption that the ACE-R 
is a more comprehensive assessment.  It is not possible to make a prediction of 
how good the ACE-R is at identifying impairment in specific domains as this has 
not previously been investigated.  However, positive results might be expected 
given the moderate-to-good correlations between scores on the ACE subscales 
and related neuropsychological tests [17].   
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Methods 
Participants were recruited from the stroke service at Nottingham City Hospital.  
This service comprises of one hyper-acute stroke ward and 3 acute stroke 
wards.  Patients were identified by examination of the medical notes held on the 
wards.  The main inclusion criterion into the study was a confirmed diagnosis of 
stroke, determined by a CT scan.  Patients were excluded from the study if they 
had a history of psychiatric problems or if they were blind, deaf, or too ill or 
drowsy (determined in consultation with the ward nurses).  Patients were also 
excluded if they did not speak English, or if they had moderate or severe 
aphasia as tested by the Sheffield Screening Test for Acquired Language 
Disorders [20] (see appendix 1.4), scoring below the age-related cut-off scores 
stated in the manual.  These patients would have been unable to complete the 
cognitive assessments.  Demographic information was obtained from the 
medical records for each eligible patient, comprising; age, gender, date of 
stroke, type and hemisphere of stroke (determined by CT scan), presence of 
hemiparesis (determined by medical examination), presence of hemianopia 
(determined by the Ophthalmologist), and functional ability (determined by the 
Barthel Index [21], administered by an Occupational Therapist).     
 
Patients who were eligible for the study were first administered an ACE-R 
screening test (which includes the MMSE).  This was carried out mainly by a 
Research Assistant or Assistant Psychologist, although in some cases, patients 
had already been administered an ACE-R by a junior doctor, in which case a 
copy was retrieved from the medical file.  Up to this point, informed consent for 
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participation in the study was not sought as the ACE-R was carried out as part 
of routine clinical practice.  After patients had received an ACE-R they were 
approached for full neuropsychological testing and, at this time, informed 
consent for the study was sought.  Each participant received a battery of ‘gold 
standard’ neuropsychological tests, selected for their proven validity and 
appropriateness for use with neurological patients (see appendix 1.5).  The 
neuropsychological test battery was administered in a consistent order 
comprising of; the Logical Memory subtest from the Wechsler Memory Scales III 
(WMS III) [22] to assess verbal memory, the Rey-Osterrieth Complex Figure 
test (recall) [23] to assess visual memory, the Star Cancellation test from the 
Behavioural Inattention Test [24] to assess visual neglect, the Rey-Osterrieth 
Copy task [23] to assess visuo-spatial perception, the Hayling Sentence 
Completion test [25] and a Verbal Fluency test (F,A,S) [26] to test executive 
functioning, and the Letter-Number Sequencing and Digit Span subtests from 
the WMS-III as measures of attention.    Neuropsychological testing lasted 
approximately one hour per participant, and was carried out by a Trainee 
Clinical Psychologist who was blind to the participants’ ACE-R scores.  The 
tests were scored and interpreted by the Trainee Clinical Psychologist, under 
the supervision of a qualified Clinical Psychologist.  The majority of tests were 
scored according to the scoring procedures and norms presented in each test 
manual.  The exceptions were the Hayling Sentence Completion and F,A,S 
tests which were interpreted using alternative norms, derived from populations 
with a greater number of older adults [27,28].  Percentile scores for each test 
were derived using the published means and standard deviations.  Patients 
were classified as impaired on a test if they scored below the fifth percentile.  
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The exception to this was if it was deemed likely that a patient failed a particular 
test due to a different cognitive problem or a non-cognitive problem (in this case 
the test was classed as void).  Following interpretation, the results were fed 
back to patients verbally, and patients were given information regarding the 
nature of their specific impairments and compensation strategies.  Written 
reports were provided for the medical team and filed in the notes.  (The 
recruitment procedure is summarised in the diagram in Appendix 1.6.)   
 
Data was analysed using SPSS version 14.  Demographic data and descriptive 
data for the test results were calculated.  Next, analysis focussed on 
determining the diagnostic validity of the MMSE and ACE-R for detecting overall 
cognitive impairment at published cut-offs of 27 and 24 (MMSE), and 88, 82 and 
75 (ACE-R).  Sensitivity and specificity was determined by comparison with the 
presence of cognitive impairment as indicated by the neuropsychological test 
battery (impairment in any one or more of the tests).  Positive and negative 
predictive values were calculated to determine the accuracy of the tests taking 
into account base rates of cognitive impairment in stroke.  Receiver Operating 
Curves were also plotted to summarise the overall hit rate of diagnoses (i.e. the 
probability that the result for a randomly chosen positive case will exceed the 
result for a randomly chosen negative case).  Following this, analysis of validity 
focused on the ACE-R individual subscales.  This was determined by similar 
methods, comparing impairment on ACE-R subscales with impairment on tests 
measuring equivalent cognitive domains in the neuropsychological test battery.  
Performance on the ACE-R Attention and Orientation subscale was compared 
to the presence of impairment on either on WAIS-III Digit Span and/ or WAIS-III 
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Letter-Number Sequencing.  The Memory subscale was compared to presence 
of impairment on either WAIS-III Logical Memory and/or Rey Figure Recall).  
The Fluency subscale was compared to presence of impairment on either FAS 
and/or impairment on the Hayling Sentence Completion test (indicated by failure 
on part two of the test, in the absence of failure on part one which controls for 
word finding difficulties and processing speed).  Finally, the Visuospatial 
subscale was compared to impairment on either Star Cancellation and/or Rey 
Figure Copy.  The ACE-R language subscale was not examined as the 
presence of aphasia had been used as one of the exclusion criteria. 
 
Ethical approval for the study was obtained by the National Research Ethics 
Service, Nottingham Research Ethics Committee 1.  No significant risks or 
adverse effects were identified for research participants in the study.  Minor or 
routine ethical issues, such as informed consent, were managed appropriately, 
and approved by the Research Committee (see Appendix 1.7.) 
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Results 
There were 64 stroke patients who were identified as meeting the inclusion and 
exclusion criteria for the study.  All these patients completed the ACE-R/MMSE 
screen as part of routine clinical care.  However 24 (34%) patients did not go on 
to complete the full neuropsychological test battery; 22 (92%) of these patients 
were discharged from hospital before they could be tested, it was discovered 
one patient was illiterate and another became unwell during testing.  Thus the 
final number of patients recruited into study was 40.  T-tests and chi-square 
analysis showed that there were no significant differences between the 
recruited and non-recruited patients in terms of demographic variables or 
performance on the screening tests (see appendix 2.1 and 2.2). 
 
Demographic information 
Of the 40 patients recruited to the study, 21 were male and 19 were female.  
The median age was 78 years (IQR 15.5), and the median years of education 
was nine years (IQR 1).  Fifteen (38%) patients had Lacunar stroke (LACS), 
seven (17.5%) had Total Anterior Circulation Stroke (TACS), eight (20%) had 
Partial Anterior Circulation Stroke (PACS), four (10%) had Posterior Circulation 
Stroke (POCS) and type of stroke was unknown for six (15%) patients.  Twenty-
four (60%) patients had right hemisphere stroke, 14 (35%) had left hemisphere 
stroke, and hemisphere of stroke was unknown for two (5%) patients.  
Hemiparesis was present in 18 (45%) patients, absent in 20 (50%) patients and 
unknown for two (5%) patients.  Hemianopia was present in 13 (33%) patients, 
absent in 25 (63%) patients and unknown for 2 (5%) patients.  The median 
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score on the Barthel Index at recruitment was nine (IQR 5.5).  The median 
interval between stroke and receiving the screening measure was 14 days (IQR 
25.3).  The median interval between receiving the screening measure and the 
neuropsychological test battery was two days (IQR 6).  The median interval 
between stroke and receiving the neuropsychological test battery was 18 days 
(IQR 27.5). 
 
Descriptive data 
Table 1 shows the descriptive results from the screening tests and the 
neuropsychological test battery.  The number of patients impaired on the MMSE 
and ACE-R varied according to the cut-off score used.  According to the 
neuropsychological test battery, 31 (78%) patients were found to have cognitive 
impairment in at least one cognitive domain.  The most common type of 
impairment found was perceptual impairment, with 23 (61%) patients impaired 
on either the Star Cancellation or Rey Figure Copy task.  Executive impairment 
was almost as common, with 22 (60%) patients impaired on either the FAS or 
Hayling Sentence Completion task.  A total of 14 (47%) patients had impairment 
on either the verbal or visual memory recall tasks, and only four (11%) patients 
had impairment on the tasks of attention (Digit Span or Letter-Number 
Sequencing).   
 
Analysis showed that performance on the MMSE, ACE-R and the 
neuropsychological test battery was not significantly related to age, gender, 
hemisphere of stroke, presence of hemiparesis, presence of hemianopia, years 
of education, score on the Barthel Index, and the number of days between 
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stroke and administration of test.  However, there was a significant relationship 
between type of stroke (LACS, TACS, PACS, and POCS) and performance on 
the MMSE, F(3,30)= 5.5, p< 0.05, and performance on the ACE-R, F(3,30)= 
4.16, p<0.05.  The relationship between type of stroke and impairment on the 
neuropsychological test battery approached significance levels, x²(3, N=34)= 
6.94, p=0.07.  (See appendix 2.1 and 2.3 for full description of analysis). 
 
Validity analysis 
First, the diagnostic validity of the MMSE and ACE-R was examined in relation 
to the presence of overall cognitive impairment as classified by the 
neuropsychological test battery (impairment in one area of cognitive 
functioning).  (See Appendix 2.4 for crosstabulations of impairment on the 
screening tests and the neuropsychological test battery.)  Sensitivity and 
specificity values for the ACE-R and MMSE (at the published cut-offs) are 
reported in Table 2.  Alongside, are corresponding positive and negative 
predictive values for the base rate of cognitive impairment reported in acute 
stroke [1].  Table 2 shows that none of the published cut-off scores give both 
adequate levels of sensitivity (>80%) and specificity (>60%).  A cut-off of 27 on 
the MMSE and 82 on the ACE-R are, arguably, the least poor.  On the MMSE, a 
cut-off of 27, gives good rates of sensitivity (81%), although unsatisfactory 
levels of specificity (22%).  On the ACE-R, a cut-off of 82, gives fair levels of 
sensitivity (77%), but unsatisfactory specificity (44%).  The positive and 
negative predictive values were very similar for both tests at all cut-offs.  
Positive predictive values were between 70-80%, indicating reasonable 
accuracy for positive results, but negative predictive values were all below 50%, 
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indicating poor accuracy for negative results.  Further analysis revealed that no 
alternative cut-offs provided suitable levels of specificity (>80%) and sensitivity 
(>60%).  (See Appendix 2.5 for sensitivity and specificity rates at a full range of 
cut-offs.)  Receiver operating curves are presented in Figure 1.  The area under 
the curve (AUC) indicates that, overall, both tests have inadequate diagnostic 
accuracy, performing no better than chance (MMSE AUC= 0.57, p> 0.05; ACE-
R AUC= 0.58, p> 0.05).   
   
Secondly, the diagnostic validity of four ACE-R subscales was examined in 
relation to the presence of impairment on tests measuring equivalent cognitive 
domains in the neuropsychological test battery.  (See Appendix 2.6 for 
crosstabulations of impairment on the ACE-R subscales and cognitive domains 
measured by the neuropsychological test battery.)  Sensitivity and specificity for 
each ACE-R subscale are presented in Table 3.  These were calculated 
according to the cut-offs published in the ACE-R manual, which varies 
according to age of each patient.  For all subscales, sensitivity is good (>80%) 
and for the Attention and Orientation subscale, sensitivity is excellent (100%).  
Specificity is unsatisfactory for all subscales (<60%).  Further analysis revealed 
that no alternative cut-offs could be found for any subscale which gave a 
specificity of >60% whilst retaining sensitivity of >80%.  (See Appendix 2.7 for 
sensitivity and specificity rates for each subscale at a full range of cut-offs.)  
Receiver operating curves are presented in Figure 2.  Although all subscales 
had consistently poor levels of specificity, the Area Under the Curve statistic 
indicated that, overall, using most of the subscales to predict impairment in 
specific areas was better than guessing;  Attention and Orientation (AUC=0.84, 
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p< 0.05), Fluency (AUC=0.72, p< 0.05) and Visuospatial (0.71, p< 0.05).  The 
memory subscale was the exception, performing statistically no better than 
chance (AUC=0.58, p> 0.05).  
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Discussion 
 
 
In comparison with the detailed neuropsychological battery of tests, neither the 
ACE-R nor the MMSE could detect the presence of cognitive impairment with 
adequate levels of sensitivity, as well as specificity.   At the higher published 
cut-off scores, both tests yielded fair-good levels of sensitivity, but levels of 
specificity were inadequate, yielding high numbers of false positive diagnoses.  
No alternative cut-offs could be identified which increased specificity without 
compromising sensitivity.  Area Under the Curve statistics indicated that, 
overall, the diagnostic accuracy of the tests was not much better than chance, 
meaning the diagnosis would be wrong in nearly 50% of cases.  Given the high 
base rates of cognitive impairment in acute stroke (70%), it is therefore more 
accurate to assume all patients have cognitive impairment, without even doing 
any tests, because you would only misdiagnose 30% of cases. 
 
Compared to performance on individual cognitive domains of the 
neuropsychological test battery, none of the ACE-R subscales examined could 
identify impairment with both adequate sensitivity and adequate specificity.  All 
subscales gave good-excellent sensitivity at the published cut-offs, but 
specificity was unsatisfactory, giving high rates of false positives.  No suitable 
alternative cut-offs were identified.  Area Under the Curve statistics indicated 
that, overall, the diagnostic accuracy of the scales was adequate, with the 
exception of the memory scale.  We can thus retain only limited confidence that 
the ACE-R subscales can accurately assist in identifying the pattern of cognitive 
impairment in stroke. 
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 The failure of both tests in this study appears to lie with poor specificity and, 
therefore, high rates of false positive diagnoses.  These findings are contrary to 
what was predicted.  Given previous literature, it was correctly predicted that the 
MMSE would perform poorly in a stroke population [1].  However, it was 
expected the ACE-R would perform better than the MMSE given its superior 
performance in related fields [16,18], and its wider coverage of cognitive 
domains.  It is possible that certain characteristics of an acute stroke population 
have led to both screening tests having poor specificity compared to in a 
dementia population.  Factors such as physical ill health and the anxiety of 
being in hospital, may have resulted in patients finding the MMSE/ACE-R too 
difficult and caused them to fail for reasons other than cognitive impairment.  
Such factors may have impacted particularly on the orientation, attention and 
memory sections which are heavily weighted in the MMSE/ACE-R.  
Unfortunately, this does not explain why previous studies of the MMSE in acute 
stroke have found poor sensitivity, rather than poor specificity [1,11].  Therefore, 
it is useful to consider how methodological shortcomings in the current study 
may have contributed to findings, especially the contrary findings of poor 
specificity. 
 
One limitation of this study is the interval between the administration of the 
screening tests and the neuropsychological test battery (median= 2 days (IQR 
6).  In a population where recovery is rapid, this may have resulted in relatively 
better performance on the neuropsychological test battery, leading to incorrect 
false positive diagnoses on the screening tests (poorer specificity).  However, 
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the fact that performance on screening and neuropsychological tests was not 
related to number of days since stroke, makes this hypothesis less likely to be 
true.  Also, whilst one of the previous studies of the MMSE in stroke had no time 
lag between the MMSE and test battery [1], the other study [11], had a time lag 
of up to three months and still found the MMSE to have good specificity. 
 
A second limitation of the current study is the relatively small sample size (40) 
and in particular, the small proportion of non-impaired patients (nine) compared 
to impaired patients (31).  In previous studies investigating the MMSE in stroke 
[1,11], and the ACE/ACE-R in dementia [16,17], samples were much larger and 
included a better mix of impaired/non-impaired patients.  In fact, most studies 
[1,16,17] included a non-impaired control group for comparison.  Therefore, it is 
possible that the small sample size and imbalance of non-impaired/impaired 
patients in the current study may have lead to inadequate statistical power and 
falsely inflated rates of poor specificity.   
 
A third limitation is that three of the nine patients who were classified as 
unimpaired by the neuropsychological test battery, did not manage to complete 
all tests due to non-cognitive problems such as poor hearing or onset of feeling 
unwell.  We cannot be 100% certain these three patients would not be impaired 
on the tests they did not complete.  These patients may have incorrectly 
contributed to high false positive classifications on the screening tests.   
 
A forth limitation to the study is a possible recruitment bias due to the high 
attrition rates between the administration of the screening tests and the 
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neuropsychological test battery.  This may have resulted in a final sample which 
is poorly representative of an acute stroke population, with a bias of more 
impaired patients.  However, the proportion of impaired patients in this study 
(78%) is similar to that found previously (70%) [1], making this less likely.  
Furthermore, analysis indicated that, in terms of demographic variables or 
performance on the screening tests, there were no significant differences 
between patients who completed the battery and those who did not.   
 
A final point worth considering is whether, rather than the MMSE/ACE-R lacking 
in specificity, the neuropsychological test battery was lacking in sensitivity.  One 
area of failure in the battery may have been the tests chosen to measure 
attention, i.e., Digit Span and Letter-Number-Sequencing.  These tests only 
measure one aspect of attention, working memory, and do not measure other 
facets of attention, i.e. focused attention, sustained attention, selective 
attention, and divided attention.  Similarly, another area of weakness in the 
battery may have been in the tests chosen to measure executive functioning 
(Hayling Sentence Completion and F,A,S).  Although these are well validated 
measures, they only really measure one aspect executive functioning which is 
cognitive flexibility/selective inhibition.  There are other aspects of executive 
functioning, e.g. planning ability and abstract thinking, which the test battery did 
not measure.  Further to this, the test battery did not include any measure of 
language.  This was a deliberate decision as language impairment, measured 
on the Sheffield Screening Test, had been an exclusion criterion, in order that 
language did not confound performance on other tests.  However, patients were 
only excluded if they had moderate-severe aphasia and it is possible that 
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patients with less severe language impairments were included in the study.  The 
test battery would, therefore, have been relatively insensitive to these 
impairments, especially in comparison to the ACE-R which includes a large 
language component within the total score.   
 
See Appendix 3.1 for discussion on how limitations could be addressed.  
 
To summarise, the current study found both the MMSE and the ACE-R to have 
inadequate validity for the detection of cognitive impairment in stroke, 
particularly demonstrating poor levels of specificity.  The ACE-R subscales 
showed a similar pattern of performance.  Poor specificity of the screening 
measures in stroke may be due to certain characteristics of this population 
causing failure on the tests for reasons other than cognitive impairment.  Given 
some limitations in the current study, including a small sample size, future 
research may aim to address limitations and replicate these findings.  Further to 
this, future research should focus on the identification of an alternative 
screening measure, or adaptation of an existing measure for suitability in stroke.  
In the meantime, there remains no support for the use of the MMSE or the ACE-
R when screening for cognitive impairment in acute stroke.   
 
(See appendix 3.2 for further discussion on the implications of this research for 
Clinical Psychology services in stroke.  See appendix 3.4 for reflections on the 
epistemological positioning of this research). 
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Key points: 
• There was no support for the use of the MMSE or the ACE-R when 
screening for cognitive impairment in acute stroke.   
• Further research is needed to identify an alternative screening measure with 
adequate levels of sensitivity and specificity. 
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Tables and figures 
 
 
Table 1.  Descriptive data from the screening tests and neuropsychological 
assessments 
  
Assessments n Mean SD Range  Impaired 
n       % 
      
Screening tests      
    MMSE  40 24.4 3.6 17-30 
                 cut-off= 27  32 (80%)
                 cut-off= 24  19 (48%)
    ACE-R  40 70.9 14.0 38-88 
                 cut-off= 88  40 (100%)
                 cut-off= 82  29 (73%)
                 cut-off= 75  23 (58%)
     ACE-R Attention and Orientation     40 15.3 2.2 9-18 26 (65%)
     ACE-R Visuospatial  39 11.7 4.0 0-16 29 (74%)
     ACE-R Fluency  40 7.1 2.9 3-12 30 (75%)
     ACE-R Memory  40 15.7 4.2 5-25 31 (78%)
      
Neuropsychological assessments      
    (Overall) - - - - 31 (78%)
    Star cancellation 38 49.3 10.3 7-54 9 (24%)
    Rey Figure Copy 37 22.0 11.4 0.5-36 22 (60%)
    FAS 40 27.2 11.6 6-55 4 (10%)
    Hayling Sentence Completion 
(errors)  
36 8.6 4.7 0-15 20 (56%)
    Logical Memory- immediate recall 40 24.3 10.4 6-44 9 (23%)
    Logical Memory- delayed recall 40 10.7 6.4 0-24 10 (25%)
    Rey Figure- immediate recall 26 7.3 5.0 0-19 10 (39%)
    Rey Figure- delayed recall 26 7.4 5.0 0-19 10 (39%)
    Digit Span 40 15.8 3.4 6-23 0 (0%)
    Letter-Number Sequencing 38 7.2 3.0 2-14 4 (11%)
      
 
MMSE= Mini-Mental State Examination 
ACE-R= Addenbrooke’s Cognitive Examination-Revised 
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Table 2.  Validity of the MMSE and ACE-R for detecting overall cognitive 
impairment 
 
Test/cut-off  Sensitivity Specificity  PPV NPV (base 
rate=70%) 
       
MMSE        
             27  81% 22%  71% 33% 
             24  52% 67%  78% 37% 
ACE-R        
             88  100% 0%  70%    - 
             82  77% 44%  77% 46% 
             75  58% 44%  71% 31% 
       
Acceptable levels of sensitivity and specificity are highlighted 
 
MMSE= Mini-Mental State Examination 
ACE-R= Addenbrooke’s Cognitive Examination-Revised 
 
 
 
Table 3.  Validity of the ACE-R subscales 
 
ACE-R subscale/ cut-offs (by age group) Sensitivity Specificity 
   
Attention and Orientation (17,17,16)* 100% 39% 
Memory (18,19,17)* 85% 31% 
Fluency (9,8,9)* 82% 36% 
Visuospatial (15,14,14)* 87% 46% 
   
Acceptable levels of sensitivity and specificity are highlighted 
 
ACE-R= Addenbrooke’s Cognitive Examination-Revised 
* cut-offs applied to each patient according to age (50-59 years, 60-69 
years,70+ years respectively). 
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ROC curve for ACE-R and 
overall cognitive impairment
ROC curve for MMSE and 
overall cognitive impairment
           
Figure 1.  Comparisons between the screening tests and overall cognitive 
impairment on the neuropsychological test battery 
 
 
 
 ROC curve for ACE-R ‘Attention 
and Orientation’ and attention 
ROC curve for ACE-R ‘Memory’ 
and memory 
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ROC curve for ACE-R ‘Fluency’ 
and executive functioning 
ROC curve for ACE-R 
‘Visuospatial’ and perception  
 
                    
 
Figure 2.  Comparison between ACE-R subscales and impairment on cognitive 
domains on the neuropsychological test battery 
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Guidelines for authors submitting to the journal ‘Age and Ageing’ 
 
The research paper is written with a view to submit for publication to the Journal 
of Age and Ageing.  This journal stipulates papers should be written according 
to the uniform requirements for manuscripts submitted to biomedical journals.  
These guidelines are presented below: 
 
Abstract and Key Words 
An abstract (requirements for length and structured format vary by journal) 
should follow the title page. The abstract should provide the context or 
background for the study and should state the study’s purposes, basic 
procedures (selection of study subjects or laboratory animals, observational and 
analytical methods), main findings (giving specific effect sizes and their 
statistical significance, if possible), and principal conclusions. It should 
emphasize new and important aspects of the study or observations. 
Because abstracts are the only substantive portion of the article indexed in 
many electronic databases, and the only portion many readers read, authors 
need to be careful that abstracts reflect the content of the article accurately. 
Unfortunately, many abstracts disagree with the text of the article (6). The 
format required for structured abstracts differs from journal to journal, and some 
journals use more than one structure; authors should make it a point prepare 
their abstracts in the format specified by the journal they have chosen. 
Some journals request that, following the abstract, authors provide, and identify 
as such, 3 to 10 key words or short phrases that capture the main topics of the 
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article. These will assist indexers in cross-indexing the article and may be 
published with the abstract. Terms from the Medical Subject Headings (MeSH) 
list of Index Medicus should be used; if suitable MeSH terms are not yet 
available for recently introduced terms, present terms may be used. 
Introduction 
Provide a context or background for the study (i.e., the nature of the problem 
and its significance). State the specific purpose or research objective of, or 
hypothesis tested by, the study or observation; the research objective is often 
more sharply focused when stated as a question. Both the main and secondary 
objectives should be made clear, and any pre-specified subgroup analyses 
should be described. Give only strictly pertinent references and do not include 
data or conclusions from the work being reported. 
Methods 
The Methods section should include only information that was available at the 
time the plan or protocol for the study was written; all information obtained 
during the conduct of the study belongs in the Results section. 
Selection and Description of Participants.  Describe your selection of the 
observational or experimental participants (patients or laboratory animals, 
including controls) clearly, including eligibility and exclusion criteria and a 
description of the source population. Because the relevance of such variables 
as age and sex to the object of research is not always clear, authors should 
explain their use when they are included in a study report; for example, authors 
should explain why only subjects of certain ages were included or why women 
were excluded. The guiding principle should be clarity about how and why a 
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study was done in a particular way. When authors use variables such as race or 
ethnicity, they should define how they measured the variables and justify their 
relevance. 
Technical information.  Identify the methods, apparatus (give the manufacturer’s 
name and address in parentheses), and procedures in sufficient detail to allow 
other workers to reproduce the results. Give references to established methods, 
including statistical methods (see below); provide references and brief 
descriptions for methods that have been published but are not well known; 
describe new or substantially modified methods, give reasons for using them, 
and evaluate their limitations. Identify precisely all drugs and chemicals used, 
including generic name(s), dose(s), and route(s) of administration. 
Authors submitting review manuscripts should include a section describing the 
methods used for locating, selecting, extracting, and synthesizing data. These 
methods should also be summarized in the abstract. 
Statistics.  Describe statistical methods with enough detail to enable a 
knowledgeable reader with access to the original data to verify the reported 
results. When possible, quantify findings and present them with appropriate 
indicators of measurement error or uncertainty (such as confidence intervals). 
Avoid relying solely on statistical hypothesis testing, such as the use of P 
values, which fails to convey important information about effect size. 
References for the design of the study and statistical methods should be to 
standard works when possible (with pages stated). Define statistical terms, 
abbreviations, and most symbols. Specify the computer software used. 
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Results 
Present your results in logical sequence in the text, tables, and illustrations, 
giving the main or most important findings first. Do not repeat in the text all the 
data in the tables or illustrations; emphasize or summarize only important 
observations. Extra or supplementary materials and technical detail can be 
placed in an appendix where it will be accessible but will not interrupt the flow of 
the text; alternatively, it can be published only in the electronic version of the 
journal. 
When data are summarized in the Results section, give numeric results not only 
as derivatives (for example, percentages) but also as the absolute numbers 
from which the derivatives were calculated, and specify the statistical methods 
used to analyze them. Restrict tables and figures to those needed to explain the 
argument of the paper and to assess its support. Use graphs as an alternative 
to tables with many entries; do not duplicate data in graphs and tables. Avoid 
non-technical uses of technical terms in statistics, such as “random” (which 
implies a randomizing device), “normal,” “significant,” “correlations,” and 
“sample.” 
Where scientifically appropriate, analyses of the data by variables such as age 
and sex should be included. 
Discussion 
Emphasize the new and important aspects of the study and the conclusions that 
follow from them. Do not repeat in detail data or other material given in the 
Introduction or the Results section. For experimental studies it is useful to begin 
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the discussion by summarizing briefly the main findings, then explore possible 
mechanisms or explanations for these findings, compare and contrast the 
results with other relevant studies, state the limitations of the study, and explore 
the implications of the findings for future research and for clinical practice. 
Link the conclusions with the goals of the study but avoid unqualified 
statements and conclusions not adequately supported by the data. In particular, 
authors should avoid making statements on economic benefits and costs unless 
their manuscript includes the appropriate economic data and analyses. Avoid 
claiming priority and alluding to work that has not been completed. State new 
hypotheses when warranted, but clearly label them as such. 
References 
General Considerations Related to References.  Although references to review 
articles can be an efficient way of guiding readers to a body of literature, review 
articles do not always reflect original work accurately. Readers should therefore 
be provided with direct references to original research sources whenever 
possible. On the other hand, extensive lists of references to original work on a 
topic can use excessive space on the printed page. Small numbers of 
references to key original papers will often serve as well as more exhaustive 
lists, particularly since references can now be added to the electronic version of 
published papers, and since electronic literature searching allows readers to 
retrieve published literature efficiently. 
Avoid using abstracts as references. References to papers accepted but not yet 
published should be designated as “in press” or “forthcoming”; authors should 
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obtain written permission to cite such papers as well as verification that they 
have been accepted for publication. Information from manuscripts submitted but 
not accepted should be cited in the text as “unpublished observations” with 
written permission from the source. 
Avoid citing a “personal communication” unless it provides essential information 
not available from a public source, in which case the name of the person and 
date of communication should be cited in parentheses in the text. For scientific 
articles, authors should obtain written permission and confirmation of accuracy 
from the source of a personal communication. 
Some journals check the accuracy of all reference citations, but not all journals 
do so, and citation errors sometimes appear in the published version of articles. 
To minimize such errors, authors should therefore verify references against the 
original documents. Authors are responsible for checking that none of the 
references cite retracted articles except in the context of referring to the 
retraction. For articles published in journals indexed in MEDLINE, the ICMJE 
considers PubMed the authoritative source for information about retractions. 
Authors can identify retracted articles in MEDLINE by using the following search 
term, where pt in square brackets stands for publication type: Retracted 
publication [pt] in PubMed.  
Reference Style and Format.  The Uniform Requirements style is based largely 
on an ANSI standard style adapted by the National Library of Medicine (NLM) 
for its databases. Authors should consult National Library of Medicine’s Citing 
Medicine for information on NLM’s recommended citation formats for a variety 
of reference types.  
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References should be numbered consecutively in the order in which they are 
first mentioned in the text. Identify references in text, tables, and legends by 
Arabic numerals in parentheses. References cited only in tables or figure 
legends should be numbered in accordance with the sequence established by 
the first identification in the text of the particular table or figure. The titles of 
journals should be abbreviated according to the style used in Index Medicus. 
Consult the list of Journals Indexed for MEDLINE, published annually as a 
separate publication by the National Library of Medicine. The list can also be 
obtained through the Library's web site. Journals vary on whether they ask 
authors to cite electronic references within parentheses in the text or in 
numbered references following the text. Authors should consult with the journal 
that they plan to submit their work to. 
Tables 
Tables capture information concisely, and display it efficiently; they also provide 
information at any desired level of detail and precision. Including data in tables 
rather than text frequently makes it possible to reduce the length of the text. 
Type or print each table with double spacing on a separate sheet of paper. 
Number tables consecutively in the order of their first citation in the text and 
supply a brief title for each. Do not use internal horizontal or vertical lines. Give 
each column a short or abbreviated heading. Authors should place explanatory 
matter in footnotes, not in the heading. Explain in footnotes all non-standard 
abbreviations. For footnotes use the following symbols, in sequence: 
*,†,‡,§,||,¶,**,††,‡‡ 
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Identify statistical measures of variations, such as standard deviation and 
standard error of the mean.  Be sure that each table is cited in the text.  If you 
use data from another published or unpublished source, obtain permission and 
acknowledge them fully. 
Additional tables containing backup data too extensive to publish in print may 
be appropriate for publication in the electronic version of the journal, deposited 
with an archival service, or made available to readers directly by the authors. In 
that event an appropriate statement will be added to the text. Submit such 
tables for consideration with the paper so that they will be available to the peer 
reviewers. 
Reference 
International Committee of Medical Journal Editors, 2007. Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals: Writing and 
Editing for Biomedical Publication. Retrieved September 25, 2008, from 
www.icmje.org
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Appendix 1.1 Stroke and cognitive impairment 
 
Stroke is defined as ‘a focal (or at times global) neurological impairment of 
sudden onset, and lasting more than 24 hours (or leading to death), and of 
presumed vascular origin’ (World Health Organisation, 1978).  Stroke affects 
over 130,00 people in the UK every year and is the third most common cause of 
death.  Stroke survivors may face a range of physical impairments following a 
stroke including, limb weakness, paralysis, muscle spacisity, pain, difficulty 
controlling bladder and bowels, problems swallowing and impaired vision.  In 
addition, impairments of cognitive functioning are extremely common.  
Following the early stages post-stroke, impairments may improve over time as 
the brain recovers, or they may persist, causing long term disabilities (The 
Stroke Association, 2006).   
 
‘Cognitive functioning’ is a term used to describe the abstract processes 
controlled by the brain such as language, perception, memory, reasoning, 
attention, psychomotor abilities (co-ordination of action), and ‘executive’ 
functions.  (Executive functions is the name given to a number of higher order 
cognitive processes such as planning ability, abstract thinking, selective 
inhibition and cognitive flexibility.  These are thought to be important in the 
execution of many everyday behaviours and in particular, the ability to respond 
adaptively in novel situations (Lezak, 2004).)  Different cognitive functions are 
subserved by different parts of the cortex and subcortex.   
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As stroke can potentially cause damage to any part of the brain, a wide range of 
cognitive impairments are observed in stroke.  Cognitive impairment is 
frequently focal in stroke, causing impairment in specific areas of functioning.  
However, depending on the location of stroke, or if there have been a series of 
strokes, there may be multiple impairments of cognition.  Multiple impairment 
following stroke is known as vascular dementia (or ‘multi-infarct dementia’).  
The DSM IV diagnostic criteria for dementia is impairment in memory, plus 
impairment in one of the following areas of cognition; language, psychomotor 
skills, perception, executive functioning (American Psychiatric Association, 
1994).  Thus, following stroke, patients with cognitive impairment can be 
classified into two groups; vascular cognitive impairment not dementia (VCIND) 
and vascular dementia (VaD). 
 
The reported prevalence of cognitive impairment in stroke has differed, and 
studies have varied according to sample size, time since stroke, and the tests 
used to assess cognitive impairment.  Nys et al. (2005a) report prevalence rates 
using a sample of 34 patients, in the early stages post-stroke (average 6.5 
days).  A strength of this study, above others, is the broad range of 
neuropsychological tests used to determine impairment.  Cognitive domains 
assessed were abstract reasoning, verbal memory, executive functioning, visual 
perception and construction, visual memory and language.  In this study, the 
prevalence of cognitive impairment in one or more areas of cognitive functioning 
was found to be 70%.  In a later study, Nys and colleagues reported that the 
risk of cognitive impairment varies according to location of stroke.  In patients 
with cortical stroke, the risk of cognitive impairment is greatest at 74%.  Patients 
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with subcortical and infratentorial stroke have a risk of cognitive impairment of 
46% and 43% respectively (Nys et al., 2007b).  
 
Reports vary as to the most commonly impaired areas of cognition in the acute 
phases post-stroke, and findings are subject to the different methods used 
between studies.  For example, in Nys et al. (2005a), the most common 
cognitive impairments were reported to be disorders of abstract reasoning 
(47%), followed by impairments in executive functioning (32%), language 
(26%), visual perception and construction (21%), verbal memory (15%) and 
visual memory (12%).  However, Lesniak, Bak, Czepiel, Seniow and 
Czlonkowska (2008) report very different findings.  This study measured 
patients at a similar time post-stroke to Nys et al. (2005a) (during the second 
week), but used a larger sample (200 patients), and a different battery of tests.  
They found that the most common cognitive impairment was attentional 
functioning (48.5%), followed by language (27%), short term memory (24.5%), 
and executive functioning (18.5%).  A review of the literature in this area cites 
executive functioning as the most commonly affected area (Engstad, Viitanen & 
Almkvist, 2007).  However, this review includes studies which either use poorly 
validated measures of cognitive impairment and/or examine a smaller range of 
cognitions.  Therefore, overall, we cannot make any conclusions as to the most 
commonly affected areas of cognition post stroke. 
 
Following the acute stages of stroke, many patients with cognitive impairment 
recover, whilst in some patients deficits remain stable, and in some patients 
deficits deteriorate further.  In a longitudinal study, Appelros and Andersson 
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(2006) found 32% of patients with cognitive impairment had deteriorated further 
after one year, 13% had remained unchanged, and 55% had improved.  Three 
months post-stroke, Madureira, Guerreiro and Ferro (2002) found that 55% of 
all stroke patients were impaired on at least one domain of cognitive 
functioning, as measured on a comprehensive neuropsychological battery of 
tests.   Of these impaired patients, 49% had VCIND and 6% had VaD.  Patel, 
Coshall, Rudd and Wolfe (2003) assessed patients at three months, one, two 
and three years post stroke and found rates of cognitive impairment to be 39%, 
35%, 30% and 32% respectively.  It is possible, however, that the rates found 
by Patel et al. may be underestimated due to use of a limited degree of 
cognitive testing in this study.  Prognosis has been found to be most favourable 
for impairments in perception/construction and visual memory, and cognitive 
recovery has been found to be associated with age, pre-existing ability, lesion 
volume, lesion location and diabetes (Nys et al, 2005b).   
 
The presence of cognitive impairment has a significant impact on an individual’s 
life post-stroke. Impairments in cognitive functioning post-stroke are strongly 
associated with a person’s ability to carry out tasks of daily living (ADLs) and an 
ability to live independently, regardless of the person’s physical ability 
(Claesson, Linden, Skoog & Blomstrand, 2005; Nys et al., 2005c).   
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Appendix 1.2 Principles of cognitive screening in acute stroke 
 
Thorough neuropsychological assessment of cognitive impairment is time 
consuming, costly and can prove too tiring or too difficult for unwell or very 
impaired patients.  In the early stages post stroke, rapid improvement also 
means that any assessment is invalidated after a relatively short period of time.  
Thus, in acute stroke, it is more appropriate, in the first instance, to use a brief 
cognitive screening measure to identify those people with cognitive problems 
and to highlight areas for more in depth assessment.  The screening measure 
should be quick and easy to administer, suitable for bedside (hospital) 
administration, and suitable to be given by staff without specialised training in 
assessment.  Cognitive screening for all stroke patients is recommended by the 
National Clinical Guidelines for Stroke (Royal College of Physicians of London, 
2004). Whilst the guidelines do not specify which screening instrument should 
be used, it is advised that clinicians select a measure that has suitable validity 
(appropriateness for the purpose).   
 
A test used for diagnosis or screening should have good diagnostic validity, i.e. 
ability to accurately detect presence of impairment in a given population.  This 
requires high levels of sensitivity and high levels of specificity (Loong, 2003).  
Sensitivity refers to how good a test is at correctly identifying those people in a 
population who have the impairment or disease (i.e. proportion of true positives 
identified by the test).  Specificity refers to how good a test is at correctly 
identifying those people who do not have the impairment or disease (i.e. 
proportion of true negatives identified by the test).  Thus a sensitivity of 80% 
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means the test will correctly detect the impairment/disease in 80% of those 
people affected, and it will miss 20% of people affected.  A specificity of 90% 
means the test will correctly classify 90% of unimpaired people as being 
unimpaired, and 10% of unimpaired people will be misclassified as impaired 
when they are not.  Sensitivity and specificity are statistically linked and trade-
off each other.  Therefore, increasing the sensitivity of a test (i.e. by lowering cut 
off scores) decreases specificity.  Diagnostic measures, as opposed to 
screening measures, should generally have a sensitivity of greater than 80% 
and a specificity of greater than 60% (Lincoln, Nicholl & Flannaghan, 2003).  In 
a screening test, which pre-empts full testing, it may be better to increase 
sensitivity to 90%, in order to detect most of those people with problems.  
However, it is important that specificity is not compromised too much, as low 
specificity will lead to full testing on lots of people who do not have impairment.  
This would mean the screening test would have little purpose, and it would be 
as well to do the full testing on everyone (Lincoln et al., 2003).    The ‘Area 
Under the Curve’ (AUC) statistic is sometimes used in studies to summarise the 
sensitivity and specificity of a test.  This figure refers to the overall ability of a 
test to correctly classify those people with or without the disease, specifically, 
the probability that the result for a randomly chosen positive case will exceed 
the result for a randomly chosen negative case).  AUC=1 is a perfect test 
(meaning 100% sensitivity and 100% specificity), .90-1 is excellent, .80-.90 is 
good, .70-.80 is fair, .60-.70 is poor and AUC 0.5 is worthless (suggesting 
discriminative ability is the same as chance).     
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When considering the diagnostic validity of a test, it is also useful to consider 
positive and negative predictive power statistics (Loong, 2003).  A positive 
predictive value takes all positive test results (true positives and false positives), 
and describes the chance of a positive test result being correct.  Negative 
predictive values take all negative results, and describe the chances of a 
negative result being correct.  Predictive power statistics take into account not 
only the diagnostic accuracy (sensitivity and specificity) of the test, but also the 
natural prevalence (‘base rate’) of impairment or disease in a population.  This 
is important because base rates can affect the likelihood of a true positive or 
true negative result, over and above the accuracy of the particular test being 
used.  For example, in a population where there is high prevalence of 
impairment, a positive test result is more likely to be correct compared to a 
positive test result using the same test in a population with a low prevalence 
rate, regardless of the accuracy of the test.  In an acute stroke population, high 
base rates of cognitive impairment of around 70% (Nys et al. (2005a) will 
naturally contribute towards higher positive predictive power, and lower 
negative predictive power.  Considering base rates alone, we can be 70% 
confident that a person will have cognitive impairment, but only 30% confident a 
person doesn’t have cognitive impairment.  It might therefore be assumed that 
there is little clinical value to using a screening measure in stroke which has a 
PPV of less than 70% or a NPV of less than 30%.   
 
To summarise, a screening test should have good positive and negative 
predictive values as well as high sensitivity and specificity.  A shortcoming of 
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many existing validity studies is a failure to report positive and negative 
predictive values. 
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Appendix 1.3 Commonly used cognitive screening measures 
 
1.3.1 The MMSE  
The MMSE (Folstein, Folstein & McHugh, 1975) is currently the most widely 
used screening measure in acute stroke (Shulman, Hermann & Brodaty, 2006).  
The MMSE was designed to screen for cognitive impairment in a range of 
medical patients including dementia and psychiatric patients.  Its purpose is to 
detect the presence and severity of cognitive impairment, and to map 
deteriorations and improvements over time.  The test takes approximately five 
minutes to administer and comprises of 11 items assessing, orientation, verbal 
memory recall, attention, language and perception/construction.  The test 
produces a total score out of 30.  Validity studies of the MMSE have identified 
two optimal cut-off scores for the detection of cognitive impairment (27 and 24).  
It is recommended clinicians use the higher or lower cut-off depending on the 
patient population and whether the clinician is more anxious to avoid false 
negatives or false positives.  A lower cut-off of 24 is recommended for 
circumstances where it is necessary to ensure high diagnostic specificity, for 
example, when discriminating between dementia and other possible causes of 
cognitive impairment such as depression (e.g. Folstein et al., 1975; Yang, 
Hwang, Jen & Liu, 2000).   
 
Although, the MMSE was designed to detect cognitive impairment in a range of 
medical conditions, by far its most common usage is for screening for dementia 
in community geriatric populations.  A wealth of studies have examined the 
validity of the MMSE in this field, most studies using populations of Alzheimer’s 
type dementia (DAT) or mixed dementia populations.  On the whole, studies 
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have shown the MMSE to have high levels of diagnostic validity for detecting 
dementia (e.g. Tombaugh & McIntyre, 1992).  For example, Helkala et al. 
(2002), found the MMSE (cut-off score of 24) to have sensitivity of 82% and 
specificity of 64% (compared with diagnosis achieved through medical history, 
neurological exam, neuropsychological tests, MRI, CSF, ECG, chest exams and 
blood tests).     
 
Despite this, the MMSE has been found to have several limitations, including 
inaccurate diagnosis of early/mild impairment, and variation of normal scores 
according to age, IQ and cultural background (Tombaugh & McIntyre, 1992; 
Nadler, Richardson & Malloy, 1994; Bieliauskas, Depp, Kauszler, Steinberg & 
Lacy, 2000; Starr & Lonie, 2007; Trenkle, Shankle & Azen, 2007).  The MMSE 
has also been shown to have limitations for the accurate detection of cognitive 
impairment in dementias and other organic disorders with subcortical 
impairment, frontal lobe impairment, or right hemisphere dysfunction (Naugle & 
Kawczak, 1989; Dick et al., 1994; Grace et al., 1995; Darvesh & Freedman, 
1996).  In acute stroke populations, which tend to characterise the above 
patterns of impairment, diagnostic validity is also poor (Blake, McKinney, 
Treece, Lee & Lincoln, 2002; Nys et al., 2005a).  
 
Nys et al. (2005a) found that at a cut-off score of 24, the MMSE had fair 
specificity (70%), but extremely poor sensitivity (34%) for the detection of 
cognitive impairment in stroke.  No alternative cut off scores on the MMSE 
could yield both a sensitivity of greater than 80% and a specificity of greater 
than 60%.  Overall, when differentiating patients with cognitive impairment and 
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those without, the MMSE performed statistically no better than chance, AUC of 
0.67 (p=0.13).  Blake et al. (2002) found the MMSE, at a cut-off of 24, had 
better levels of sensitivity and specificity in acute stroke (62% and 88% 
respectively), although this still represents inadequate levels of sensitivity.  
However, Nys et al. (2005a) criticised the methodology of this study, 
highlighting the large individual differences in intervals between the 
administration of the MMSE and the neuropsychological examination used to 
determine the presence of impairment (up to 3 months).  Given that recovery is 
greatest in the first three months post-stroke, Nys et al. (2005a) suggested that 
patients may have performed much better on the neuropsychological 
examination, thus over estimating the sensitivity of the MMSE in this study.  In 
addition, as Blake et al. (2002) noted, patients did not complete a standard 
selection of tests as part of their neuropsychological examination, in order to 
limit time spent on testing.  This means that there is a possibility that patients 
may have performed, overall, better on the neuropsychological examination 
relative to their true ability, further overestimating the sensitivity of the MMSE. 
 
The poor validity of the MMSE in acute stroke, compared to in dementia 
populations (consisting mainly of DAT), is probably explained by inadequate 
assessment of different domains of cognitive functioning.  Compared to DAT, 
there is a more heterogeneous range of impairments seen in stroke, due to both 
cortical and subcortical impairments, and the existence of focal as well as global 
impairments.  The MMSE assesses only a narrow range of cognition (verbal 
memory recall, attention, language and perception/construction), omitting any 
measure of executive functioning and assessing very few performance abilities.  
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Nys et al. (2005a) found that, compared to detailed neuropsychological 
assessments, the MMSE was most likely to miss impairments in reasoning, 
executive functioning, and visual perception/construction.   
 
Besides having poor validity, another limitation of the MMSE in stroke is that it 
only provides normative data for the overall score, and it does not have norms 
for individual subscales.  Therefore, it only has the capacity to identify the 
presence or absence of cognitive impairment per se, and it is not possible to 
make any quantitative conclusions about severity of impairment in specific 
areas of cognitive functioning (e.g. memory).  It is also not reliable to make 
qualitative conclusions from performance on subtests as the subtests of the 
MMSE have been found to have poor domain specificity (Giordani, Boivin, Hall 
& Foster, 1990; Tierney, Szalai, Snow, Fisher & Dunn, 1997).  A measure of 
this kind has disadvantages in a stroke population.  Here, it is less relevant to 
know whether someone has cognitive impairment per se (it already likely they 
do due to high base rates).  It is more useful to know what specific problems 
exist, in order to inform rehabilitation and provision of care.  Domain specific 
cognitive abilities in acute stroke also have prognostic value in terms of long 
term cognitive and functional outcomes (Nys et al., 2005c). 
 
To summarise, the MMSE was designed for the detection of cognitive 
impairment in a wide range of medical conditions.  It is most commonly used in 
community geriatric patients for the detection of dementia (mainly DAT), where 
its diagnostic validity has been found to be good.  However the MMSE has 
limited validity for the detection of cognitive impairment in organic conditions, 
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such as stroke, where impairment is more heterogeneous than in DAT.  This is 
probably due to the assessment of a restricted range of cognitive domains.  
Furthermore, the MMSE has restricted utility in stroke because it is unable to 
give information about the nature of cognitive impairment in individuals.  
 
1.3.2  The Cambridge Cognitive Examination ( CAMCOG).   
The CAMCOG forms part of the Cambridge Mental Disorders of the Elderly 
Examination (CAMDEX) (Roth et al., 1986).  This screening test was designed 
specifically to assess the range of cognitive functions required for a diagnosis of 
dementia.  It is a more comprehensive screening measure compared to the 
MMSE, with more items, covering a larger number of cognitive domains 
(orientation, language, memory, attention, praxis, calculation, abstract thinking 
and perception).  The CAMCOG comprises of all items of the MMSE plus 
additional questions, yielding a MMSE score out of 30 and a CAMCOG score 
out of 106.  Clinicians can also calculate scores for several individual cognitive 
domains allowing analysis of relative impairment in specific areas.      
 
In the original validation study (Roth et al., 1986), the authors found that a 
CAMCOG total cut-off score of 79/80 was optimal for the discrimination of 
demented patients (DAT, VaD or other dementias) from non-demented patients.    
This CAMCOG cut-off score gave a sensitivity of 92% and specificity of 96%.     
In comparison, the optimal MMSE cut-off score in this study was found to be 
23/24 which gave similar levels of sensitivity (94%) but poorer specificity (85%).  
Unlike the MMSE, the CAMCOG did not show ceiling effects and was sensitive 
to milder degrees of cognitive impairment.  Similar results have been reported in 
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later studies (Blessed, Black, Butler & Kay, 1991; Huppert, Brayne, Gill, Paykel 
& Beardsall, 1995).   
 
De-Koning et al. (1998) have also shown the CAMCOG to have excellent 
validity for the detection of dementia syndrome in a post-stroke population.  The 
overall diagnostic accuracy of the CAMCOG in this study for detecting dementia 
was found to be 95% (AUC = 0.95), which was somewhat superior to the 
MMSE (AUC=0.90).  (The authors did not report sensitivity and specificity 
values for specific cut-off scores.)  Despite its promising psychometric 
properties for use in stroke populations, a major disadvantage of the CAMCOG 
for use in stroke is the time taken to administer the test (approximately 25 
minutes). 
 
To summarise, the CAMCOG offers a more comprehensive assessment of 
cognitive functioning compared to the MMSE, and it has been shown to have 
superior diagnostic validity for the detection of dementia.  However, the trade-off 
for this is longer administration time. 
 
1.3.3 The Rotterdam-Cambridge Cognitive Examination (R- CAMCOG).     
De-Koning, Dippel, van-Kaooten and Koudastall (2000) aimed to address the 
shortcomings of the CAMCOG by developing a shortened version, the 
‘Rotterdam-CAMCOG’ (R-CAMCOG) for use in stroke.  This new measure 
takes just 10 minutes to administer, with the reduction in length achieved by 
removing items with floor and ceiling effects and items with poor diagnostic 
validity.  A preliminary analysis of the validity of the R-CAMCOG on the dataset 
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used to develop the test suggested the R-CAMCOG to have equal levels of 
overall diagnostic accuracy as the CAMCOG (AUC= 0.95 for both tests) (de-
Koning et al., 2000).  An optimal cut-off score of 33/34 was recommended for 
the detection of post-stroke dementia.   
 
In a later, separate, validation study, analysis confirmed the R-CAMCOG to 
have good validity for the detection of dementia post-stroke at the 
recommended cut-off; sensitivity= 66% and specificity= 94% (de-Koning, van-
Kooten, Koudstaal & Dippel, 2005).  A short-coming of this study, however, was 
the failure to compare this with validity of the MMSE within the same sample.  
Instead, the authors compared figures to those found in their earlier study (de 
Koning et al., 1998).  This indicates the R-CAMCOG to have better specificity 
than the MMSE (94% verses 84%), but slightly worse sensitivity (66% verses 
69%).  Unfortunately, the authors do not make a comparison with the validity of 
the CAMCOG found in the earlier study, and it is not possible for the reader to 
do so independently as different statistics are reported in the two studies.   
 
Despite minor methodological shortcomings, the findings of de-Koning and 
colleagues are encouraging, suggesting that the R-CAMCOG may have good 
diagnostic accuracy for the detection of dementia post-stroke.  However, it is 
important to note that de-Koning et al.’s studies only examined validity for 
detecting dementia post-stroke (VaD), and they did not look at ability to detect 
VCIND.  Thus, we do not know how good the CAMCOG/R-CAMCOG would be 
at detecting impairments in an inclusive stroke population.   
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Given that there is no measure of executive functioning in these tests, it seems 
reasonable to predict that the CAMCOG/R-CAMCOG may be less accurate at 
identifying cognitive impairment in a stroke population which includes patients 
with VCIND.  Like the MMSE, the CAMCOG/R-CAMCOG may misdiagnose 
patients whose impairments are characterised by problems in executive 
functioning (Nys, 2005a).  This probably limits the potential of the CAMCOG as 
a screening test for all stroke patients.  A further limitation of this test as a 
screen in stroke is that it requires specialised test equipment, making it 
unsuitable for bedside administration.  
 
To summarise, the R-CAMCOG is a shortened version of the CAMCOG, 
designed specially for the detection of dementia post-stroke.  Validity studies 
have suffered from some methodological short-comings but indicate 
comparable levels of validity compared to both the CAMCOG and the MMSE.  
However, its utility for the detection of cognitive impairment in inclusive acute 
stroke populations remains unclear due to lack of studies, and its potential for 
this purpose may be limited due to the omission of a measure of executive 
functioning.  Furthermore, the test is likely to be impractical as a screening 
measure, requiring specialised test equipment. 
 
1.3.4  The Addenbrooke’s Cognitive Examination (ACE).   
The ACE (Mathuranath, Nestor, Berrios, Rakowicz & Hodges, 2000) was 
developed in order to overcome the limitations of the MMSE and the CAMCOG, 
that is, to provide a measure which is sensitive to a larger range of cognitive 
impairment, a measure sensitive to mild degrees of impairment, and a measure 
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suitable for bedside administration.  In addition, the ACE was designed to detect 
and differentiate Alzheimer’s disease (DAT) and frontotemporal dementia 
(FTD).  The ACE comprises the MMSE plus additional items which expand on 
memory, language and visuospatial components.  It also includes a measure of 
executive functioning (verbal fluency) which the MMSE omits.  Six cognitive 
domains are assessed in total; Attention, Orientation, Memory, Fluency, 
Visuospatial and Language.   The memory section evaluates episodic memory 
(recall of three items from the MMSE plus name and address learning) and 
semantic memory.  The language component assesses naming (of line 
drawings), comprehension, repeating spoken words, reading words and writing 
a sentence.  The visuospatial component consists of copying overlapping 
pentagons (from the MMSE), copying a wire cube and drawing a clock face.  
The fluency section comprises of a letter fluency and category fluency test.  The 
ACE gives a total score out of 100, as well as a MMSE score, out of 30, making 
it easy to compare performance to previous MMSE scores documented by other 
clinicians.  In addition to total scores, the ACE also gives scores on the six 
subscales.  Maximum scores are; orientation (10 points), attention (eight 
points), memory (35 points), verbal fluency (14 points), language (28 points), 
and visuospatial ability (five points).  The ACE is a test requiring only pen and 
paper and takes between 15 and 20 minutes to administer.   
 
 
In the original validation study (Mathuranath et al., 2000), normative data was 
provided for the ACE from a sample of 127 patients from non-dementia clinics 
(orthopaedic and gynaecological clinics).  139 patients from a dementia clinic 
were also recruited and the ACE was examined for its ability to accurately 
discriminate the presence of dementia in the whole sample.  Validity was 
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compared to the MMSE and reliability of the ACE was also examined.  
Diagnosis of dementia had been determined by CT or MRI scan, laboratory 
evaluation, and neuropsychiatric/neuropsychological test batteries.  Dementia 
diagnoses were of mixed type including; AD, VaD, FTD dementia with Lewy 
bodies, and corticobasal degeneration.  
 
The validity of the ACE for detecting dementia was considered at a range of cut-
off scores.  The first cut-off score examined was a score of 88, which represents 
the mean score of the control group plus two standard deviations.  At this cut-
off, the ACE had a sensitivity of 93% and a specificity of 71% for detecting 
dementia.  Analysis determined an alternative cut-off of 83 which enhanced 
specificity (96%), whilst compromising sensitivity (82%).  Predictive values at a 
range of reported prevalence rates were reasonably high for both cut-off scores.  
In comparison, the optimal cut-off score on the MMSE was found to be 27, 
yielding a sensitivity of 74% and a specificity of 96%.  A cut-off of 24 on the 
MMSE yielded comparable levels of specificity (96%), whilst greatly reducing 
sensitivity (52%).  The reliability of the ACE was measured in terms of internal 
consistency.  Cronbach’s alpha for the ACE was very good (0.78). 
 
Mathuranath et al. (2000) concluded that the ACE had better sensitivity, but 
equal levels of specificity compared to the MMSE for detecting dementia.  The 
ACE was particularly superior compared to the MMSE when using the lower 
cut-offs (83 and 24 respectively).  The authors recommended use of an ACE 
cut-off score of 88 in populations where it is more important to reduce false 
negatives (i.e. clinical settings, particularly where the base rate of dementia is 
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high), and use of a cut-off score of 83 where it is more important to reduce false 
positives (e.g. screening for a therapeutic trial or in clinical settings where the 
base rate for dementia is low).   
 
On the basis of further sub-group analysis, the authors also concluded that the 
ACE maintained good sensitivity for diagnosing different severity and types of 
dementia.  The ACE proved particularly advantageous over the MMSE at 
detecting FTD patients, nearly doubling the detection rate.  Furthermore, the 
calculation of a ‘VLOM’ ratio (ratio of scores on Fluency plus Language to 
Orientation plus name and address delayed recall memory) could accurately 
discriminate FTD from non-FTD patients.   
 
Further to the original validation study, Dudas (2005) compared the ACE scores 
of patients who had cognitive impairment due to dementia and the ACE scores 
of patients who had cognitive impairment due to affective disorder.  The results 
showed that the total ACE scores of the dementia groups were significantly 
lower (<88) compared to total ACE scores of the affective disorder group.  In 
addition, the patient groups differed in their subscales profiles; patients with 
affective disorder presented with mild impairment on ACE total scores plus low 
memory and fluency scores, whilst patients with dementia were characterised 
by low total ACE scores.  Thus adding to the findings of the original study, this 
study indicates that, not only can the ACE can differentiate dementia patients 
from controls, but it can also differentiate dementia patients from other patients 
with cognitive impairment.   
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One limitation of the index study (Mathuranath et al., 2000) was its reliance on 
cross-sectional data in a patient group where a dementia diagnosis is only ever 
‘probable’ and diagnosis, as determined by the gold standard clinical 
assessment, occasionally changes over time.  Larner (2005, 2006) addressed 
this limitation by undertaking a longitudinal audit in a Cognitive Function Clinic, 
publishing two consecutive papers, examining different properties of the ACE.   
 
Larner’s first paper (Larner, 2005) reported the ability of the ACE to discriminate 
the presence of dementia in 154 consecutive new patients referred to the clinic.  
Diagnosis of dementia was confirmed with a standard patient and informant 
semi-structured interview, formal neuropsychological assessment and structural 
brain imaging (CT or MRI scan).  Patients had mixed dementia diagnoses 
including DAT, FTD, VaD, VCIND, dementia with Lewy bodies and alcohol-
related dementia.  This study very much replicated the index study in design, 
with the key difference being that patients had a minimum of six months follow-
up to confirm or establish diagnosis.    At follow-up, 80 patients were found to 
have dementia, and 78 patients were not demented.  For the diagnosis of 
dementia, an ACE cut-off score of 88 in this study gave a sensitivity of 97% and 
specificity of 47%.  A cut-off score of 83 gave a sensitivity of 92% and specificity 
of 62%.  A MMSE cut-off score of 27 gave a sensitivity of 91% and a specificity 
of 70%, and a MMSE of 24 gave a sensitivity of 73% and a specificity of 86%.  
Thus the ACE offered greater sensitivity but lesser specificity than the MMSE.  
In comparison to the index study (Mathuranath et al., 2000), the results are 
similar in terms of sensitivity but worse in terms of specificity.  The author 
pointed out that the poor specificity may be due to the unselected nature of the 
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patient cohort in their study.  All patients had cognitive dysfunction of some kind 
(hence being referred to a cognitive dysfunction clinic) and thus many would fail 
the screens for reasons other than dementia e.g. depression.   
 
In a second paper, Larner (Larner, 2006) reported the ability of the ACE for 
tracking cognitive change over time in 23 patients whose diagnoses had 
originally been uncertain.  Patients were administered the ACE between 2-5 
times over a 7-36 month period.  As previously, an initial clinical diagnosis was 
based on standard patient and informant semi-structured interview, formal 
neuropsychological assessment and structural brain imaging (CT or MRI scan).  
Clinical diagnosis at the end of the follow-up period was based on care-giver 
report and clinical judgement.  The author compared the diagnostic accuracy of 
the first ACE scores to the diagnostic accuracy of the final ACE scores.  
Comparing the first and last assessments, sensitivity and specificity rates 
remained comparable and positive predictive values improved.  Larner (2006), 
whilst acknowledging the small sample size in this cohort, suggests that the 
ACE is responsive to longitudinal change in dementia.   
 
To summarise, the ACE was developed as a bedside screening measure which 
would overcome the limitations of the MMSE, specifically, assessing a wider 
range of cognitive domains and allowing more in-depth analysis by the provision 
of subscale scores.  Validity studies have indicated that the ACE has superior 
sensitivity compared to the MMSE in the detection of dementia, but comparable 
or marginally worse levels of specificity.  Analysis of the ACE subscales enable 
the accurate discrimination of different types of cognitive impairment, and the 
ACE is sensitive to longitudinal change in cognition.   
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 1.3.5  The Addenbrooke’s Cognitive Examination-Revised (ACE-R).   
Since the ACE, a revised version of the ACE, the ACE-R, has been published, 
which has now superseded the use of the ACE in clinical practice (Mioshi, 
Dawson, Mitchell, Arnold & Hodges, 2006).  In developing the ACE-R, the ACE 
underwent several design modifications in order to make it easier and quicker to 
administer, to increase the test sensitivity and to facilitate cross cultural usage 
and translation.  In addition, three different versions of the ACE-R were 
designed to allow for repeat testing.  Modifications to the content of the test 
included major changes to the memory component, reducing its weight in the 
overall score and allowing other domains to have a more balanced contribution.  
The fluency scoring system was adjusted, and some changes to the language 
section were made, including increasing the difficulty of the naming task.  The 
visuospatial section was expanded to include counting of dot arrays and 
identification of fragmented letters.  There were no changes to the attention and 
orientation sections.  The maximum score on the ACE-R remains 100, but the 
subscales are five instead of six, with attention and orientation being combined.  
They are weighted as follows; attention and orientation (18 points), memory (26 
points), fluency (14 points), language (26 points) and visuospatial (16 points).   
The ACE-R takes marginally less time than the ACE to administer (between 12-
20 minutes).       
 
In Mioshi et al., 2006 the methodology for the validation of the ACE-R was 
similar to that of the original ACE study (Mathuranath et al., 2000).  Control 
participants were used to create new normative data for the ACE-R total score, 
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and the diagnostic validity of the ACE-R for detecting dementia was determined 
at a variety of cut-offs.  Unlike in the original study, normative data was also 
provided for the test’s subscales to allow direct comparison of scores to normal 
controls’ performance.  A total of 241 subjects participated, completing both the 
ACE and the ACE-R.  There were 142 patients with different diagnoses of 
dementia, 36 patients with mild cognitive impairment (MCI) and 63 controls.  As 
before, diagnoses of dementia were determined by CT or MRI scan, laboratory 
evaluation, and neuropsychiatric/neuropsychological test batteries.  Diagnosis 
of MCI was determined by performance on cognitive and functional tests and 
clinical interview.   
 
In Mioshi et al. (2006) two possible ACE-R cut-off scores were identified in this 
study (88 and 82).  At 88 the ACE-R gave excellent sensitivity (94%) and good 
specificity (89%) for the detection of dementia.  A cut-off score of 82 reduced 
sensitivity (84%), whilst increasing specificity (100%).  A cut-off of 82 gave 
perfect positive predictive value (100%) at all the prevalence rates investigated, 
whilst at a cut-off of 88, the ACE-R had lower positive predictive value, 
especially at low prevalence rates.  Diagnostic validity of the ACE-R was not 
compared with that of the ACE or the MMSE in this study population, although 
given the methodology is similar to that in the original ACE study, one can 
assume a fair comparison.  Considering the sensitivity and specificity rates 
reported in the early study, the ACE-R performed better than both the ACE and 
the MMSE at both high and low cut-offs, with the exception of the MMSE having 
better specificity at the higher cut-off of 27.  The authors of this study did 
compare mean scores of participants on the ACE and the ACE-R, finding that 
there was indeed a significant difference in total ACE/ACE-R scores and on 
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most subscales.  Thus, the authors concluded that the ACE-R resulted in better 
sensitivity and specificity and had striking levels of positive predictive value for 
detecting dementia at a range of prevalence rates.   
 
Extended analysis in Mioshi et al. (2006) revealed significant differences in 
scores between dementia and MCI subjects, and between MCI and control 
subjects, suggesting the ACE-R is also sensitive to detecting MCI.  The authors 
suggested, on the basis of clinical experience, a cut-off of 80 could be used for 
detecting MCI.  In addition, analysis of the ‘VLOM’ ratio indicated that the ACE-
R, like the ACE, could accurately discriminate FTD from non-FTD patients, 
although the authors noted specificity is much better than the sensitivity when 
used for this purpose. 
 
Whilst Mioshi et al’s finding were promising, they acknowledged that the study 
was developed within a very specialised population of patients (university 
clinic), and recommended that the ACE-R also be studied in community 
samples where disease characteristics and prevalence rates may be different.  
Larner (2007) conducted a pragmatic study of the ACE-R reflecting more day-
to-day clinical practice.  As in early studies by the same author, this study 
recruited patients from a cognitive function clinic, where there was no selection 
of patients by disease category, no application of exclusion criteria, and no 
control group of normal individuals- all patients had some form of cognitive 
dysfunction.  The study examined the ability of the ACE-R to identify patients 
with a dementia (types included DAT, FTD, VaD and dementia with Lewy 
bodies), at the previously published cut-offs of 88 and 82.  Compared to the 
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index study (Mioshi et al, (2006), the author found the ACE-R to have better 
sensitivity at both cut-offs of 88 and 82 (100% and 96% respectively).  However, 
specificity rates were much poorer (48% and 72% respectively), as were 
positive predictive values (62% and 75% respectively).  Given the different case 
mix of this sample compared to the index study (i.e. all patients had some form 
of cognitive impairment), the author felt justified to investigate a lower cut-off 
value (75).  At this cut-off, excellent sensitivity was maintained (91%), specificity 
was greatly improved (91%) as was positive predictive value (89%).  Thus the 
author concluded that the ACE-R had good diagnostic accuracy for detecting 
dementia in day-to-day clinical practice, but suggested lower cut-offs may be 
necessary depending on the setting and the case mix of referrals.     
 
Whilst the vast majority of studies have examined the ACE and ACE-R for use 
in dementia populations, one recent study has examined the ability of the ACE-
R to detect cognitive impairment in brain injured patients (Gaber, 2008).  This 
study comprised of a sample of 36 brain injured patients, all with cognitive 
impairments severe enough to stop the patient returning to full time 
employment.  The authors examined the ability of the ACE-R to correctly 
determine the presence of cognitive impairment in these patients at the two 
published cut-off scores of 88 and 82.  Results showed the ACE-R to have 
better sensitivity than the MMSE at both the higher cut-off (ACE-R= 72%, 
MMSE= 36%), and at the lower cut-off score (ACE-R= 56%, MMSE= 11%).  
This study is limited, however, by the absence of a non-impaired control group, 
thereby making it impossible to consider specificity levels and rates of false 
positive diagnosis.  Despite the possible limitations of this study, the fact that 
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the ACE-R seems to have, at least, good sensitivity in the field of brain injury is 
a good indication that the ACE-R may also perform well in stroke.  This is 
because the cognitive presentation of these two groups of patients share more 
similarity than either do with dementia, with high rates of subcortical and frontal 
lobe impairment.   
 
To summarise, the ACE-R was developed following modifications of the ACE 
aimed at decreasing administration time, increasing test sensitivity and 
facilitating cross-cultural usage.     The ACE-R also offers the advantage over 
the ACE of having normative data for each subscale, allowing more accurate 
analysis of patterns of impairment.  Validity studies have indicated that the 
ACE-R has increased sensitivity and specificity for the detection of dementia, 
compared to the ACE and the MMSE, although there has been some debate 
over the ideal cut-off score.  One study has also given early indications that the 
ACE-R has utility for the detection of cognitive impairment in brain injury.  The 
validity of the ACE/ACE-R has not yet been examined in stroke patients and 
this is the focus of the current study. 
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Appendix 1.4 The Sheffield Screening Test 
 
The Sheffield Screening Test for Acquired Language Disorders (Syder, Body, 
Parker & Boddy., 1993) was used to screen for aphasia, which was one of the 
exclusion criteria for the study.  The test comprises of two sections, addressing 
expressive and receptive language separately.  Each section includes five 
subtests examining specific areas of linguistic processing.  The receptive skills 
section examines; verbal comprehension of single words, comprehension of a 
sequential command, comprehension of a complex command, recognition of 
differences in meaning between words, and comprehension of narrative.  The 
expressive skills section examines; word finding, abstract word finding, 
sequencing, ability to produce word definitions and verbal reasoning.  Points are 
awarded for each correct answer and these are added to equal a total score on 
the test (max= 20).  The authors of the test found age to be a significant 
independent variable in determining scores on the test, thus they recommended 
the use of a sliding cut-off score, on the basis of age.  This attempts to 
eradicate the risk of false negatives in older people with non-pathological 
language deterioration.  The cut-off scores for impairment, used in the current 
study, as shown in the test manual are <59 years = 17, 60-69 years = 16, and 
70 + years = 15.  The authors of the Sheffield Screening test report good 
concurrent and diagnostic validity and good inter-rater reliability.  The normative 
sample was of an adequate size (n=112) and consisted of adults mostly over 
the age of 60, making it suitable for use with a stroke population, whom are 
mostly older adults.  The Sheffield Screening Test is also suitable as it can be 
used by someone who is not a speech therapist and is a brief measure. There 
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have been subsequent studies that have included validation of the Sheffield 
Screening Test. 
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Appendix 1.5  The neuropsychological test battery 
 
1.5.1  F,A,S verbal fluency  
In the neuropsychological test battery, a verbal fluency test was used as a 
measure of executive functioning.  Verbal fluency tests, originally developed by 
Berg (1948) are thought to measure cognitive flexibility (ability to selectively 
attend to relevant stimuli and filter out irrelevant stimuli).  Verbal fluency tests 
have been shown to be highly sensitive to the presence of lesions in the frontal 
lobe (the area of the brain assumed to subserve executive functioning) (e.g. 
Henry & Crawford, 2004).  They have also been found to be more sensitive to 
frontal lesions than other measures of cognitive flexibility, such as the 
Wisconsin Card Sorting test (Henry & Crawford, 2004).  A huge number of 
versions of Verbal Fluency tests have been devised since the original paradigm 
was developed by Berg (1948).  Tests commonly require subjects to generate 
words, at speed, beginning with specific letters of the alphabet, commonly F,A,S 
(phonemic fluency), or belonging to certain semantic categories (category 
fluency). The tests yield an overall score, equal to the total number of words 
produced for all three letters or categories.  In the current study, phonemic 
fluency was assessed, rather than category fluency, as category fluency, whilst 
sensitive to frontal impairments, is also sensitive to temporal lobe impairments 
i.e. language dysfunction (Henry & Crawford, 2004).  A large number of 
normative data sets exist for verbal fluency tests.  In the current study, the 
norms produced by Tombaugh, Kozak & Rees (1999) were used.  This gives 
normative data for the total number of words produced for the letters F,A,S, with 
1 minute allowed for each letter).  These norms are derived from a very large 
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sample (n=895), covering a wide age range (16-95 years).  The data is also 
stratified by age and years of education, two variables commonly known to 
significantly predict verbal fluency.  To ensure maximum validity of norms, the 
current study utilized the specific instructions used in the Tombaugh et al. 
(1999).   
  
1.5.2  Hayling Sentence Completion  
The Hayling Sentence Completion test from the Hayling and Brixton Tests 
(Burgess & Shallice, 1997) was used as another measure of executive 
functioning.  This is thought to measure two abilities; response initiation and 
response suppression, both of which have been shown to be impaired in 
patients with frontal lobe lesions.  The test consists of two sections.  In both 
sections, the examiner reads aloud sentences which have a word missing at the 
end (e.g. “the old house will be torn….”).  In section 1, subjects are required to 
complete the sentence sensibly, as quickly as possible, (e.g. “the old house will 
be torn down”).  In Section 2, subjects are required to complete the sentence as 
quickly as possible with a word which does not fit at the end of sentence, a word 
that is unconnected in meaning (e.g. “the captain wanted to stay with the 
sinking light bulb”).  The test yields three scores; the sum of latencies in section 
1 (indication of response initiation), the sum of latencies on section 2 and the 
sum of errors on section 2 (indications of response suppression).  In the original 
validation study by Burgess and Shallice (1997), the test was shown to have 
good diagnostic validity, accurately discriminating control subjects from patients 
with frontal lesions.  Inter-rater reliability was shown to be very good, and split-
half reliability was fair.  However, the normative data provided in the original 
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study was not deemed suitable for use in the current study as it is based on a 
sample which included very few older adults (66-89 years n=19).  Thus, a 
review of the literature was carried out to find an alternative normative data set.  
From this, the data provided in Bielak, Mansueti, Strauss and Dixon (2006) 
seemed the most suitable for the current study, consisting of a large sample (n= 
457) of older adults (aged 53-90).  Normative data is stratified by age in this 
study, as this was found to be a significant predictor of test performance. 
 
1.5.3  Star Cancellation  
The Star Cancellation test from the Behavioural Inattention Test (BIT) (Wilson, 
Cockburn & Halligan, 1987) was used as a measure of perception, specifically 
visuospatial neglect.  Visuospatial neglect is a phenomenon commonly 
associated with stroke in which patients fail to notice, orient, or respond to 
stimuli in one side of space (the side contralateral to the brain lesion).  The Star 
Cancellation test comprises of a sheet of A4 paper containing 52 large stars, 13 
randomly positioned letters and 10 short words, interspersed with 56 smaller 
stars.  The subjects are required to cross out all the small stars.  The examiner 
demonstrates by crossing out 2 stars in the middle section.  The maximum 
score is 54.  The normative data presented in Wilson et al. (1987) gives a 52 as 
a cut-off score for impairment.  This is based on an, adequate, sample of 50 
non-brain damaged adults, aged 22-82.  The star cancellation subtest was 
chosen to use in isolation from the whole BIT as it has been shown to have 
excellent diagnostic validity on its own.  In a sample of 80 patients, Halligan and 
Marshall (1989) found that the star cancellation subtest was sensitive to all 30 
cases of visual neglect as diagnosed on the basis of the BIT total test score.  
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Thus, there seemed little benefit to administering the full BIT for the purpose of 
this study.   
 
1.5.4 Rey-Osterrieth figure copy task  
The Rey-Osterrieth Complex Figure copy task (Rey, 1941; Osterrieth, 1944) 
was used as a second measure of perception.  This task requires subjects to 
copy a complex geometric figure onto a sheet of paper.  The specific aspect of 
perception it measures is visuospatial construction.  Visuospatial construction 
ability is required in activity such as drawing, building and assembling.  It 
requires a combination of visual perception and spatial awareness, as well as 
more executive skills such as, planning and organisation of motor response.  As 
such, patients with both parieto-occipital lesions and frontal lobe impairment 
have deficits on the Rey-Osterrieth Complex Figure copy test (Pillon, 1981).  (In 
the current study, visuospatial construction was assessed primarily as an 
indication of perception, although performance on the task was also considered 
in the evaluation of executive functioning.)  The Rey-Osterrieth Complex Figure 
copy task has been found to have good concurrent validity, correlating with 
other visuospatial tests e.g. block design and object assembly from the 
Wechsler Intelligence tests (Poulton & Moffitt, 1995).  Inter-rater reliability has 
been found to be good (Liberman, Stewart, Seines & Gordon, 1994). 
 
The Rey-Osterrieth Complex Figure test has been presented in a manualised 
format by Meyers and Meyers (1995), together with a standardised method for 
scoring and results of a normative standardization study.  The norms presented 
in Meyers and Meyers (1995) were considered suitable for use in the current 
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study, having been obtained from a large sample which includes a good 
representation of older adults (n= 601, age range = 18-89 years).   The 
normative scores are stratified by age.  (Other demographic variables, gender 
and years of education, were not found to correlate with performance). 
 
1.5.5 Logical Memory  
The Logical Memory subtest from the Wechsler Memory Scales III WMS III) 
was used to assess verbal memory (Wechsler, 1999).  This involves the free 
recall of information immediately following auditory presentation of a story.  In 
addition to immediate recall, subjects are tested for their retention of the story 
after a 30 minute delay.  Logical Memory has been reported to have good 
diagnostic sensitivity and is more sensitive than list learning tasks and a paired 
associate learning tasks at identifying impaired patients from controls (Guilmette 
& Rasile, 1995).  Inter-rater reliability has been reported to be excellent 
(Woloxzun, Murphy, Wetzel & Fisher, 1993; McGuire & Batchelor, 1998), and 
test-retest reliability is adequate (The Psychological Corporation, 1997).  The 
best norms available are those presented in the WMS III manual which are 
based on a sample of 1250 individuals aged 16-89 years (The Psychological 
Corporation, 1997). 
 
1.5.6 Rey-Osterrieth figure recall 
The Rey-Osterrieth figure (Rey, 1941; Osterrieth, 1944) was used to assess 
non-verbal memory recall, using the administration procedure and norms 
presented in the manual by Meyers and Meyers (1995).  This test requires the 
subject to draw the figure from memory 3 minutes after the copy procedure 
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(immediate recall), and again after 30 minutes (delayed recall).  A standardised 
scoring system is used to calculate scores for immediate and delayed recall, 
based on the number of elements of the figure correctly produced.  The Rey-
Osterrieth figure has good diagnostic validity, identifying patients with 
neuropsychological impairment, and loading on a visual memory factor (Berry, 
Allen, & Schmitt, 1991).  Inter-rater, alternate form, test-retest and internal 
consistency reliability are adequate-good (Berry et al., 1991).  Various versions 
of the complex figure tests exist, but results tend to be comparable.  The 
version presented in Meyers and Meyers (1995) was favoured above others as 
the corresponding norms are derived from a sample including a good 
representation of older adults. 
 
1.5.7 Digit Span test 
The Digit Span subtest from the WMS-III was used as a measure of attention 
(Wechsler, 1999).  This specifically measures short-term storage capacity, 
which is one of a number of mechanisms assumed to underlie attentional ability.  
Digit Span requires subjects to repeat increasing sequences of digits after the 
examiner, first forwards, then backwards.  Digit Span ability is intact in many 
persons with brain disorders and tends to recover quickly after damage occurs.  
The test is most sensitive to more severe brain damage, and to left hemisphere 
damage rather than right hemisphere damage. (Hom & Reitan, 1984).    
 
1.5.8 Letter-Number Sequencing  
The Letter-Number Sequencing subtest from the WMS-III was used as a 
second measure of attention (Wechsler, 1999).  This measures another 
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attentional mechanism, working memory, i.e. the ability to hold information in 
mind whilst performing a mental operation.  In this task, subjects are asked to 
repeat a series of letters and numbers (increasing in length), giving numbers 
first in numerical order, followed by letters in alphabetical order.  This requires 
subjects to keep the information in mind long enough to rearrange the order.  
Studies have shown Letter-Number Sequencing to have adequate criterion 
validity in brain injury (Donders, Tulsky & Zhu, 2001), and brain imaging studies 
have demonstrated activation in areas of the brain associated with working 
memory (Haut, Kuwabara, Leach & Arias, 2000).  Scores on Letter-Number 
Sequencing are strongly correlated with Digit Span scores, suggesting they 
measure a similar underlying construct (Crowe, 2000). 
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Appendix 1.6 Study procedure flowchart 
 
   Excluded 
 
Patients given information sheet  (A) and, after 
24 hours, consent/assent sought for data to be 
used. 
 
 Consent given Consent refused 
Group A:  
Patients who should receive 
neuropsychological testing, as part of 
routine care.  
Trainee Clinical Psychologist administers 
neuropsychological assessments as part 
of routine care 
(feedback of results to patient and team). 
 
Research Assistant/Assistant Psychologist screens patients with ACE-R as part 
of routine clinical practice 
 
Group B: 
Patients who do not require further 
neuropsychological assessments as part of 
routine care.  
Excluded  
No further action 
 
Given information sheet (B) regarding study and 
after 24 hours, consent/assent sought to receive 
neuropsychological assessments.  
 
Consent given Consent refused 
Research Assistant/ Assistant Psychologist 
examines medical notes to identify eligible 
patients.  Also administers Sheffield 
Screening Test.   
Does patient meet exclusion/inclusion 
criteria? 
             YES            NO 
Trainee Clinical Psychologist administers 
neuropsychological assessments  
Data included Data excluded 
Trainee Clinical 
Psychologist feeds 
back results to team 
and patient 
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Appendix 1.7  Ethical considerations 
 
 There were three main ethical considerations.   
 
Potential for emotional distress and fatigue  
It was recognised that some patients might experience emotional distress 
during the administration of neuropsychological assessments if tests led to the 
patient having insight into previously unrecognised cognitive impairments.  The 
chance of emotional distress was deemed to be low.  However, emotional 
distress was kept to a minimum by making explicit to patients the purpose of 
carrying out tests and the possibility that they may reveal impairments.  Also, by 
giving patients reassurance that impairments will be explained to them and that 
the identification of impairments will assist with the provision of appropriate 
interventions to aide recovery and rehabilitation.  In addition to this, there was 
risk of tests causing patients fatigue as they require concentration and mental 
effort.  Patients were advised that they could discontinue assessments if they 
were feeling too tired unwell.  They were permitted to reconvene tests at a later 
date. 
 
Confidentiality and storage of data.   
Test data and demographic information was made anonymous using a number 
coding system, and patient identifiable information (e.g. name, address, hospital 
number) was kept on a separate list to ensure confidentiality.  For the duration 
of the study, the anonymous data was kept in a locked drawer on NHS 
premises, in the Clinical Psychology office in the Nottingham City Hospital.   It 
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was also stored onto NHS and University computers for analysis.  Patient 
identifiable information was kept in a separate drawer in the Clinical Psychology 
office.  The data will be archived for 7 years after the completion of the study at 
the University of Lincoln.  It will then be destroyed. 
 
Informed Consent  
Ethical approval was received for the consent procedure and followed the 
regulations of the Mental Capacity Act (2005).  Patients who were not able to 
give informed consent, due to cognitive impairment, were not excluded from the 
study.  This is because a study examining the validity of a screening measure 
needs to include patients with a range of severity of cognitive impairment.  For 
those patients unable to give informed consent, assent was sought from a 
relative or another person known to the patient.  Information sheets were 
provided to patients (or relatives) with information about the study.  These were 
supplemented with verbal explanations where necessary.  The information 
sheets were written in simple language and large font to assist readability for 
persons with cognitive impairments or problems with vision.  Where necessary, 
capacity to consent was checked by asking the patient to explain in their own 
words their understanding of the study and what their participation would entail.  
Consent or assent was obtained in writing, where possible.  If written consent 
was not possible, e.g. due to physical impairment, verbal consent was 
witnessed by a member of the psychology or medical staff and this was 
documented in the medical notes.  Consent and assent forms were also filed in 
the medical file, and patients (or relatives) were given a copy for their reference.   
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Appendix 2 
Additional results 
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Appendix 2.1 Normality of distributions  
 
Analysis was performed on (continuous) demographic variables and screening 
test scores to check for normality of distributions.   
 
Demographic variables 
Shaprio-Wilk analysis showed that data for age and years of education was not 
normally distributed; W(31)= 0.93, p<0.05; P(32)= 0.70, p<0.05.  Data for 
Barthel scores was normally distributed, W(32)= 0.98, p>0.05.  However, being 
an ordinal scale, the data from the Barthel Index would also be treated as non-
parametric data. 
 
Performance on screening tests 
Shapiro-Wilk tests showed that the data for MMSE total scores and ACE-R total 
scores were both normally distributed; W(32)= 0.94, p>0.05; W(32)= 0.94, 
p>0.05.   
 
The data describing the number of days between stroke and administration of 
screening tests, and the number of days between stroke and administration of 
the neuropsychological test battery were not normally distributed; W(32)= 0.76, 
p<0.05; W(36)= 0.79, p<0.05.   
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Appendix 2.2  Comparison between recruited and non-recruited samples 
 
Analysis was conducted to ensure demographic variables and performance on 
the screening tests did not differ significantly between patients who were 
recruited for the full study (neuropsychological battery completed) and those 
who were not recruited (neuropsychological battery not completed). 
 
Demographic variables   
Chi-square tests were used for analysis of categorical variables.  These showed 
that the two samples did not differ significantly in gender, x²(1, N= 64)= 0.61, 
p>0.05, type of stroke, x²(3, N=52)= 3.18, p>0.05, hemisphere of stroke, x²(1, 
N=56)= 0.02, p>0.05, presence of hemiparesis, x²(1, N=60)= 1.39, p>0.05, or 
presence of hemianopia, x²(1, N=59)= 0.69, p>0.05.  Mann-Whitney U tests for 
nonparametric data were used for analysis of continuous variables.  The tests 
showed that the two samples did not differ significantly in age, U= 416.00, 
p>0.05, Barthel score, U= 286.50, p>0.05, or years of education, U= 400.50, 
p>0.05. 
 
Performance on screening tests 
Independent samples t-tests showed that there were no significant differences 
between the two groups in total score on the MMSE, t(36)= -0.70, p>0.05, or 
total score on the ACE-R, t(38)= -0.99, p>0.05.  Chi-square analysis showed 
that there were no significant difference between the two groups in the 
presence of impairment on the MMSE, as indicated by a cut-off of 24, x²(1, 
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N=64)= 0.02, p>0.05, or at a cut-off of 27, x²(1, N=64)= 1.42, p>0.05.  There 
was also no significant difference between the two groups in presence of 
impairment on the ACE-R, as indicated by a cut-off of 75, x²(1, N=64)= 0.04, 
p>0.05, or a cut-off of 82, x²(1, N=64)= 0.48, p>0.05.  With presence of 
impairment indicated by a cut-off of 88, chi-square analysis found a significant 
difference between the two groups, with more of those in the recruited sample 
being impaired that those in the non-recruited sample, x²(1,N=64)= 5.25, 
p<0.05.  However, this statistic was deemed invalid due to there being no 
persons with without impairment in the ‘recruited’ group. 
 
Further to this, a Mann-Whitney U test showed that the two samples did not 
differ significantly in the number of days between stroke and administration of 
the screening tests, U= 303.50, p>0.05. 
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Appendix 2.3  Relationships between demographic variables and 
performance on cognitive assessments 
 
Analysis was conducted to examine the relationships between demographic 
variables and overall performance on the MMSE, ACE-R, and 
neuropsychological test battery.  Different statistical tests were used for different 
variables according to the principles of parametric and non-parametric analysis.   
 
Age 
Spearman’s rank correlation showed that there was no significant relationship 
between age and total scores on either the MMSE,  r(38)= -0.15, p>0.05, or the 
ACE-R, r(38)= -0.26, p>0.05.  Mann-Whitney U analysis showed that there was 
no significant difference in median age, between those patients impaired on the 
neuropsychological test battery and those who were not impaired, U= 1.37.50, 
p>0.05. 
 
Gender 
Independent samples t-tests demonstrated that total scores on the screening 
tests did not differ significantly between male patients and female patients 
(MMSE: t(38)= -1.22, p>0.05; ACE-R: t(38)= -1.22, p>0.05).  Chi square 
analysis showed that gender did not significantly predict whether someone 
would be impaired on the neuropsychological test battery, x²(1, N=40)= 0.30, 
p>0.05. 
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Type of stroke 
Analysis of variance (ANOVA) demonstrated a significant difference in total 
scores on the MMSE, according to type of stroke, i.e. LACS, TACS, PACS and 
POCS, F(3,30)= 5.5, p< 0.05.  There was also a significant difference in total 
scores on the ACE-R, according to type of stroke, F(3,30)= 4.16, p<0.05.  Chi-
square analysis indicated that type of stroke did not significantly predict whether 
someone would be impaired on the neuropsychological test battery, x²(3, 
N=34)= 6.94, p>0.05.  However, the probability for this analysis was 
approaching significance (p= 0.07). 
 
Hemisphere of stroke 
Independent samples t-tests demonstrated that total scores on the screening 
tests did not differ significantly between patients who had left hemisphere stroke 
and those who had right hemisphere stroke (MMSE: t(36)= 0.12, p>0.05; ACE-
R: t(36)= -1.12, p>0.05).  Chi square analysis showed that hemisphere of stroke 
did not significantly predict whether someone would be impaired on the 
neuropsychological test battery, x² (1, N=38)= 2.87, p>0.05. 
 
Presence of hemiparesis 
Independent samples t-tests demonstrated that total scores on the screening 
tests did not differ significantly between patients who had hemiparesis and 
those who did not (MMSE: t(36)=0.30, p>0.05; ACE-R: t(36)= 0.70, p>0.05).  
Chi square analysis showed that presence of hemiparesis did not significantly 
predict whether someone would be impaired on the neuropsychological test 
battery, x²(1, N=38)= 2.99, p>0.05. 
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Presence of hemianopia 
Independent samples t-tests demonstrated that total scores on the screening 
tests did not differ significantly between patients who had hemianopia and those 
who did not (MMSE: t(36)= 1.19, p>0.05; ACE-R: t(36)= 1.13, p>0.05).  Chi 
square analysis showed that presence of hemianopia did not significantly 
predict whether someone would be impaired on the neuropsychological test 
battery, x²(1, N=38)= 0.75, p>0.05. 
 
Years of education 
Spearman’s rank correlation showed that there was no significant relationship 
between years of education and total scores on either the MMSE, r(35)= 0.02, 
p>0.05, or the ACE-R, r(35)= 0.14, p>0.05.  Mann-Whitney U analysis showed 
that there was no significant difference in median years of education, between 
those patients impaired on the neuropsychological test battery and those who 
were not impaired, U= 97.50, p>0.05. 
 
Score on Barthel Index 
Spearman’s rank correlation showed that there was no significant relationship 
between scores on the Barthel Index and total scores on either the MMSE, 
r(35)= 0.16, p>0.05, or the ACE-R, r(35)= 0.11, p>0.05.  Mann-Whitney U 
analysis showed that there was no significant difference in median scores on 
the Barthel Index, between those patients impaired on the neuropsychological 
test battery and those who were not impaired, U= 96.50, p>0.05. 
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Number of days between stroke and administration of test  
Spearman’s rank correlation showed that there was no significant relationship 
between the number of days since stroke and total scores on either the MMSE 
r(34)= -0.21, p>0.05, or the ACE-R, r(34)= -0.20, p>0.05.  Mann-Whitney U 
analysis showed that there was no significant difference in median days since 
stroke, between those patients impaired on the neuropsychological test battery 
and those who were not impaired, U= 99.50, p>0.05. 
 
Summary 
Performance on the MMSE, ACE-R and the neuropsychological test battery 
was not significantly related to age, gender, hemisphere of stroke, presence of 
hemiparesis, presence of hemianopia, years of education, score on the Barthel 
Index and the number of days between stroke and administration of test.  There 
was a significant relationship between type of stroke (LACS, TACS, PACS, and 
POCS) and performance on the MMSE and performance on the ACE-R.  The 
relationship between type of stroke and impairment on the neuropsychological 
test battery approached significance levels.  
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Appendix 2.4 Crosstablulations of overall impairment on tests 
 
Tables 1-5 show crosstablulations of number of patients impaired on the 
screening tests at different cut-offs, and number of patients with overall 
impairment on the neuropsychological test battery.   
 
Table 1.  MMSE (cut-off= 27) and neuropsychological test battery 
 
 
Neuropsychological 
test battery Total 
  
Not 
impaired Impaired   
MMSE (cut-off= 27) Not impaired 2 6 8 
  Impaired 7 25 32 
                              Total 9 31 40 
 
 
Table 2.  MMSE (cut-off= 24) and neuropsychological test battery 
 
 
Neuropsychological 
test battery Total 
  
Not 
impaired Impaired   
MMSE (cut-off= 24) Not impaired 6 15 21 
  Impaired 3 16 19 
                              Total 9 31 40 
 
 
Table 3.  ACE-R (cut-off= 88) and neuropsychological test battery 
 
 
Neuropsychological 
test battery Total 
  
Not 
impaired Impaired   
ACE-R (cut-off= 88) Not impaired 0 0 0 
  Impaired 9 31 40 
Total 9 31 40 
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Table 4.  ACE-R (cut-off= 82) and neuropsychological test battery 
 
 
Neuropsychological 
test battery Total 
  
Not 
impaired Impaired   
ACE-R (cut-off= 82) Not impaired 4 7 11 
  Impaired 5 24 29 
Total 9 31 40 
 
 
Table 5.  ACE-R (cut-off= 75) and neuropsychological test battery 
 
 
Neuropsychological 
test battery Total 
  
Not 
impaired Impaired   
ACE-R (cut-off= 75) Not impaired 4 13 17 
  Impaired 5 18 23 
Total 9 31 40 
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Appendix 2.5  MMSE/ACE-R sensitivity and specificity rates 
 
Tables 3 and 4 show MMSE and ACE-R sensitivity and specificity rates at a full 
range of cut-offs. 
 
 
 
 
 
 
Table 3.  MMSE sensitivity and 
specificity rates  
Table 4.  ACE-R sensitivity and 
specificity rates  
Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
 Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
16.0 0.0 100 37.0 0 100
17.5 7 100 39.0 3 100
18.5 7 78 41.5 7 100
20.0 13 78 47.0 7 99
21.5 16 78 51.5 10 99
22.5 29 78 55.0 16 99
23.5 42 78 60.0 16 78
24.5 52 67 62.5 23 78
25.5 61 56 64.0 32 78
26.5 71 44 65.5 36 78
27.5 81 22 66.5 42 78
28.5 90 11 68.0 42 67
29.5 94 0 69.5 45 67
31.0 100 0 71.0 48 67
Acceptable levels of sensitivity and 72.5 55 56
specificity are highlighted 74.5 58 44
  76.5 61 44
  78.0 65 44
  79.5 71 44
  80.5 74 44
  82.0 77 44
  83.5 77 33
  85.5 81 22
  87.5 90 22
  89.0 100 0
  Acceptable levels of sensitivity and 
  specificity are highlighted 
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Appendix 2.6  Crosstablulations of impairment on ACE-R subscales 
 
Tables 5,6,7 and 8 show crosstablulations of number of patients impaired on 
the ACE-R subscales screening tests, and number of patients impaired on 
specific domains on the neuropsychological test battery.   
 
Table 5.  ACE-R ‘Attention and Orientation’ and attention 
  
 Attention  Total 
  
Not 
impaired Impaired   
ACE-R  Not impaired  13 0 13
‘Attention and Orientation’   
  Impaired 20 4 24
  
Total 33 4 37
 
 
Table 6.  ACE-R ‘Memory’ and memory  
 
 Memory Total 
  
Not 
impaired Impaired   
ACE-R  Not impaired  5 2 7
‘Memory’   
  Impaired 11 11 22
  
Total 16 13 29
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Table 7.  ACE-R ‘Fluency’ and executive functioning 
 
 
Executive 
functioning Total 
  
Not 
impaired Impaired   
ACE-R  Not impaired  5 4 9
‘Fluency’   
  Impaired 9 18 27
  
Total 14 22 36
 
 
 
 Table 8.  ACE-R ‘Visuospatial’ and executive functioning. 
 
 Perception Total 
  
Not 
impaired Impaired   
ACE-R  Not impaired  6 3 9
‘Visuospatial’   
  Impaired 7 20 27
  
Total 13 23 36
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Appendix 2.7  Sensitivity and specificity rates for ACE-R subscales 
 
Tables 9,10,11 and 12 show sensitivity and specificity rates, at a full range of 
cut-offs, for each ACE-R subscale. 
 
Table 9.  ACE-R ‘Attention and Orientation’    Table 10.  ACE-R ‘Memory’ 
 
Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
 Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
8.0 0 100 8.0 00 100
9.5 0 97 9.5 07 100
11.0 25 94 11.0 14 88
12.5 50 94 12.5 21 88
13.5 50 88 13.5 36 88
14.5 75 82 14.5 36 56
15.5 75 71 15.5 43 56
16.5 100 47 16.5 57 44
17.5 100 15 17.5 79 44
19.0 100 0 18.5 86 25
Acceptable levels of sensitivity and  19.5 93 19
specificity are highlighted 21.5 93 13
  23.5 100 13
  25.0 100 0
  Acceptable levels of sensitivity and 
  specificity are highlighted 
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Table 11.  ACE-R ‘Fluency’           Table 12.  ACE-R ‘Visuospatial’  
 
Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
 Cut-off 
less than 
or equal 
to: 
Sensitivity 
(%) 
Specificity 
(%) 
2.0 0 100 .5 4 100
3.5 27 93 2.5 9 100
4.5 36 93 5.0 13 100
5.5 46 87 7.0 13 93
6.5 59 87 9.0 22 86
7.5 64 87 10.5 35 86
8.5 73 53 11.5 48 79
9.5 86 40 12.5 52 71
10.5 86 20 13.5 70 71
11.5 91 7 14.5 87 50
13.0 100 0 15.5 91 14
Acceptable levels of sensitivity and  17.0 100 0
specificity are highlighted Acceptable levels of sensitivity and  
  specificity are highlighted 
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Appendix 3 
Extended discussion
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Appendix 3.1  Suggestions for improved methodology 
 
One of the limitations highlighted for this study was the interval between the 
administration of the screening tests and the neuropsychological test battery 
(median= 2 days (IQR 6), which may have resulted in relatively better 
performance on the neuropsychological test battery, leading to incorrect false 
positive diagnoses on the screening tests.  The reason for this interval was 
mainly due to practical and organisational factors.  Two separate researchers 
were needed to administer the screening test and the neuropsychological test 
battery so that the researcher doing the neuropsychological test battery was 
blind to ACE-R scores.  Unfortunately, the two researchers only had a limited 
amount of time each week for involvement on the project, and were rarely 
available to administer the tests on the same day.  This meant an inevitable 
delay between the administration of the screen and the battery.  On occasions, 
this delay was enhanced further by a patient being unavailable to complete the 
neuropsychological battery on the researcher’s first visit.  If this study were 
replicated, this problem would ideally be addressed by ensuring the two 
researchers are available for testing on the same day.  Before administering the 
screening test, the researcher should check with ward staff that the patient is 
going to be available to complete the neuropsychological test later that day.   
 
A second limitation, identified, was the relatively small proportion of non-
impaired patients (nine) compared to impaired patients (31), which may have 
resulted in poor statistical power and falsely inflated rates of poor specificity.  A 
balanced sample of impaired and non-impaired patients was impossible to 
achieve through random sampling as base rates of cognitive impairment are so 
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high in stroke.  If the study were replicated, better statistical power could be 
achieved through a larger sample size.  Alternatively patients could be more 
selectively sampled to ensure a more equal proportion of unimpaired patients.  
This could be achieved, either through consultation with the ward staff regarding 
who they feel is least impaired, or by selection of patients according to stroke 
type (LACS patients are least likely to be impaired).  Another possibility is to 
make use of a group of patients who have had a transient ischemic attack (TIA), 
which is related in aetiology to a stroke but results in less cognitive impairment.    
 
A third limitation of the study was the high attrition rates between the 
administration of the screening tests and the neuropsychological test battery, 
due to patients being discharged home.  There is a possibility this may have 
resulted in a final sample which is poorly representative of acute stroke 
population with a bias of more impaired patients.  If this study were replicated 
this problem could be addressed by ensuring both the screen and battery are 
completed on the same day, as mentioned above, or by following up discharged 
patients at home.  Both solutions would require researchers having more time 
and greater flexibility in their time to give to the project. It would also be 
preferable if tests were administered during an agreed time frame post-stroke.  
This would need to be based on clinical evidence regarding the most 
appropriate time to carry out testing. 
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Appendix 3.2  Implications for Clinical Psychology practice  
in stroke services  
 
 
 
Both the MMSE and the ACE-R have been found to be invalid as measures for 
screening for cognitive impairment in acute stroke.  There is little justification for 
their continued use in stroke, especially given that, due to high base rates of 
cognitive impairment, we can predict cognitive impairment more accurately just 
by assuming all patients are impaired.  Further research may prove successful 
in identifying a more valid screening measure.  However, if, as hypothesised, 
patients fail screening tests for reasons other than cognitive impairment (i.e. 
fatigue, physical illness), we would expect to find similar poor validity for all 
tests.  The absence of any valid cognitive screening measures for use in stroke 
leads to a number of dilemmas regarding how Clinical Psychology should 
operate in this field.   
 
Presently, pressed Clinical Psychology services rely on screening tests to 
identify patients who might benefit most from a full neuropsychological 
assessment.  Given it is impossible for Clinical Psychology to administer full 
neuropsychological assessments to every acute stroke patient, there becomes 
a need to identify an alternative way of directing these scarce resources.    One 
option would be to identify patients through the functional assessments which 
are routinely carried out on the wards by Occupational Therapists and 
Physiotherapists, referring those patients who struggle with tasks for reasons 
other than physical impairment.   This could, in fact, prove to be a more 
effective way of selecting patients because, this way, only patients who are 
functionally affected by cognitive impairment are tested.  Thus, the exercise 
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becomes more practically relevant for patients, and less ‘academic’.  This would 
also avoid unnecessarily testing patients whose cognitive impairments are 
‘trumped’ by an inability to carry out ADLs due to serious physical impairments.  
The problem with this approach is that, following discharge from the ward, 
patients may continue to recover physically, and cognitive deficits, which were 
previously unnoticed may emerge.  This would also rely on Occupational 
Therapists, Physiotherapists, and other members of the MDT, being skilled in 
recognising cognitive influences on practical tasks.  Future research could 
examine the appropriateness of Clinical Psychology referrals based on 
functional performance, compared to the appropriateness of referrals based on 
performance on cognitive screening tests.  
 
A further dilemma exists around whether Clinical Psychology services should be 
assessing patients in acute stroke at all, even with detailed neuropsychological 
assessments.  A number of facts lead us to question whether this practice is 
justified.  Firstly, we have only limited evidence that the more detailed 
assessments are not invalidated by the same non-cognitive factors as 
screening measures, as only some assessments have been validated with 
acute stroke patients.  Secondly, even if neuropsychological tests are accurate 
at describing cognitive impairment, improvement in acute stroke is so rapid that 
results may be invalidated in a matter of days.  Lastly, as referred to above, 
knowing the extent of cognitive impairment may have little importance in the 
acute stages post stroke given the extent of physical impairment that many 
patients experience.  There may be more value in waiting to do 
neuropsychological assessments until after patients have experienced a decent 
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period of recovery, perhaps even waiting until they have been discharged from 
hospital.  Instead, upon leaving hospital, patients/carers could be given 
information leaflets regarding cognitive impairment, and be advised to refer for 
neuropsychological testing if problems persist.  However, a possible 
disadvantage of concentrating resources in the community might be that acute 
medical services will no longer be able to make use of information about 
cognitive problems for rehabilitation and discharge planning.  It would be useful 
if further research focused on assessing the value of Clinical Psychology at 
different stages post-stroke.  This should take into account factors such as the 
relative contribution of assessments to patient well-being, and the predictive 
validity of assessments regarding recovery and long term difficulties.   
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Appendix 3.4  Reflections on the study’s epistemological position  
 
Quantitative approaches to research are often viewed as being akin to 
‘positivism’, a philosophy of science commonly associated with Auguste Comte 
(1798-1857).  The central tenant of positivism, known as the ‘verification 
principle’, is that true statements (e.g. “the ACE-R is a valid measure of 
cognitive impairment in stroke”) are always verifiable by observation and 
measurement (Smith 1986, cited in Miller, 1999).  Thus, scientific research 
based on this principle, employs quantitative measurement to either prove or 
disprove hypotheses, ultimately aiming to find a single ‘correct’ answer to the 
question.   
 
For the current research it was deemed appropriate to undertake a quantitative 
(and thus positivistic) approach to the research question.  This is because there 
was a clear need to produce a definitive answer to a very specific clinical 
question (is the ACE-R a valid instrument for screening for cognitive impairment 
in stroke?).  It was necessary to prove or disprove this statement in order to 
justify the use of the MMSE and the ACE-R in clinical practice.  Whilst a 
quantitative (positivistic) approach was considered justified, it is important to 
acknowledge common criticisms of this approach to research. 
 
One key criticism of positivism and quantitative research is directed at the 
validity of the ‘verification principle’ itself.  This was called into question by 
Popper (1959, cited in Miller, 1999), who reasoned that it was impossible to 
ever verify a statement as being correct beyond any possible doubt.  This is 
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because, no matter how many times we find evidence to support a statement, 
there is always a chance that, in the future, we will find evidence to refute it.  
Infamously, Popper used the example of the ‘black swan’ to illustrate this point, 
saying we can’t prove all swans are white, until we have seen a black one.  
Thus, according to Popper’s theory, we cannot be certain that the finding of the 
current study (the ACE-R is an invalid measure of cognitive impairment in 
stroke) is true, because it is possible a future study will falsify this finding.  Miller 
(1999), however, suggests that Popper’s criticism of pure positivism need not 
necessarily affect the credibility of quantitative research.  Miller (1999) suggests 
that it is possible to accept the findings of quantitative research, so long as we 
also acknowledge that this reality may not be wholly accurate and 
unambiguous.  Thus, we can accept that the ACE-R is not a valid measure in 
stroke, so long as we acknowledge, that this finding is not a certainty, and that 
the measurement influencing this outcome may have been imperfect. 
 
Another key criticism of positivism and quantitative approaches, especially in 
respect to Clinical Psychology, is that by investing in the search for a definitive 
answer to a question, we reduce complex human experience to a set of 
simplistic indices (Miller, 1999).  In this respect, qualitative research is often 
favoured over quantitative research as outcomes comprise of humanistic 
descriptions, or sets of descriptions, of the broader phenomenon, rather than a 
definitive answer to a specific aspect.  Miller (1999), however, defends the use 
of quantitative research in Clinical Psychology, suggesting that reductionism is 
acceptable so long as we are clear about what specific aspect of a particular 
phenomenon we are explaining.  In relation to the current research, a narrow 
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focus and definitive (quantitative) answer about the validity of the ACE-R was 
what was required in order to inform clinical practice.  However, it is 
acknowledged that, given a different clinical focus, qualitative approaches have 
great value for exploring the experiences of stroke patients in relation to 
cognitive impairment and their experience of neuropsychological testing.  
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Appendix 4 
Patient information sheets and consent forms 
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 There were two versions of patient information sheets and consent forms.  Form 
A was given to patients who did not need to consent to neuropsychological 
testing (because completed tests as part of routine care).  These patients were 
only required to give consent for their anonymous data to be used.  Form B 
were given to patients who would not normally be required to undertake detailed 
neuropsychological testing, and therefore, needed to give consent to complete 
the tests.  Refer to appendix 1.6 for further clarification of the recruitment and 
consent process. 
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Patient Information Sheet (A) 
 
The validity of the Addenbrooke’s Cognitive  
examination- Revised (ACE-R) in Stroke 
 
Investigators : Katie Morris; Dr Vicki Hacker; Prof. Nadina Lincoln 
 
 
You are being invited to take part in a research study.  Before you 
decide it is important for you to understand why the research is 
being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends, 
relatives or your GP if you wish.  Ask us if there is anything that 
is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  
 
What is the purpose of the study? 
 
After someone has suffered a stroke, it is important to assess 
whether they have ‘cognitive’ problems e.g. problems with 
memory or language.  The aim of this study is to investigate 
whether a short screening test (ACE-R) is effective in detecting 
cognitive problems in the early stages after a stroke. 
 
Why have I been chosen? 
 
We are asking 60 people who have had a stroke recently to take 
part. 
 
What will happen to me if I take part? 
 
You will not have to do anything to take part.  You have already 
had some cognitive assessments, including the ACE-R test, as 
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part of your routine care.  We would just like your permission to 
include your results in this study. 
 
Do I have to take part? 
 
Taking part is voluntary.  It is up to you to decide.  If you decide 
not to take part, your standard of care will not be affected. 
 
What happens to me if I decide not to take part? 
 
Your results will not be included in the study. 
 
What happens if I change my mind? 
 
You can withdraw from the study at any point, without giving a 
reason.  If this happens, the information you have provided will 
not be included within our study.  Your withdrawal will not affect 
the care you receive. 
 
What are the possible benefits of taking part? 
 
There are no benefits to you.  Future stroke patients may benefit 
as the information may help to improve methods of assessing 
cognitive problems. 
 
What are the possible disadvantages of taking part? 
 
There are no particular disadvantages of taking part in the study. 
 
What if there is a problem? 
 
You can speak to a member of the research team about any 
concerns you have.  If you wish to make a formal complaint about 
any aspect of the way you have been treated during the course of 
this study, you can do this through the NHS Complaints 
Procedure. 
 
Will my taking part in the study be kept confidential? 
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All information which is collected about you during the course of 
the research will be kept strictly confidential and any information 
about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised.   
 
What will happen to the results of the study? 
 
They will be presented as a university degree thesis and presented 
for publication in a scientific journal.  Your own scores on the 
tests will not be personally identifiable in any report.  We will 
send you a summary of results of the study when it is finished 
(probably in 2009).   
 
Who is organising this study? 
 
The Stroke Service at Nottingham University Hospitals NHS 
Trust and the University of Lincoln. 
 
Who has reviewed the study? 
 
This study has been reviewed and given favourable opinion by 
…………………………..Research Ethics Committee. 
 
What happens now? 
 
Take time to decide whether you want to take part in the study.  If 
you decide to take part, you will be asked to sign a consent form.   
 
Thank you for taking time to read this. 
 
 
 
Contact information 
If you have any questions about this study you may contact: 
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Dr Vicki Hacker 
Clinical Psychologist  
Nottingham University 
Hospitals NHS Trust 
Beeston Ward 
Hucknall Road 
Nottingham 
NG5 1PB 
0115 9691169 ext.46550 
Prof. Nadina Lincoln 
Research Director 
University of Nottingham 
William Lee Buildings 8 
Science & Technology Park 
Nottingham 
NG7 2RQ 
0115 9515315 
Miss Katie Morris  
Trainee Clinical Psychologist 
University of Lincoln 
Health, Life and Social Sciences 
Court 11, Satellite Building 8 
Brayford Pool 
Lincoln 
LN6 7TS 
01522 886029 
 
 
 
 
Patient Information Sheet (B) 
 
The validity of the Addenbrooke’s Cognitive  
examination- Revised (ACE-R) in Stroke 
 
Investigators : Katie Morris; Dr Vicki Hacker; Prof. Nadina Lincoln 
 
 
 
You are being invited to take part in a research study.  Before you 
decide it is important for you to understand why the research is 
being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends, 
relatives or your GP if you wish.  Ask us if there is anything that 
is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  
 
What is the purpose of the study? 
 
After someone has suffered a stroke, it is important to assess 
whether they have ‘cognitive’ problems e.g. problems with 
memory or language.  The aim of this study is to investigate 
whether a short screening test (ACE-R) is effective in detecting 
cognitive problems in the early stages after a stroke. 
 
Why have I been chosen? 
 
We are asking 60 people who have had a stroke recently to take 
part. 
 
What will happen to me if I take part? 
 
You have already had the ACE-R test.  We would like to compare 
these results with the results of more detailed tests.  You will be 
0809, RES, Research Project, UofL: 06060035, UofN: 4059149, page 120 of 145 
asked to complete a number of tasks that assess a range of 
memory and thinking abilities.  These usually take 30-40 minutes 
to complete.  The tests will be completed in a quiet room on the 
ward with a researcher.  If you wish, a carer or another member of 
staff may be present during the testing.  Your results will be 
explained to yourself and, if you wish, to the medical staff.  
 
Do I have to take part? 
 
Taking part is voluntary.  It is up to you to decide.  If you decide 
not to take part, your standard of care will not be affected. 
 
What happens to me if I decide not to take part? 
 
You will not need to complete any more tests at this time.  Any 
further assessments, which you undertake as part of your routine 
care, will not be included in the study. 
 
What happens if I change my mind? 
 
You can withdraw from the study at any point, without giving a 
reason.  If this happens, the information you have provided will 
not be included within our study.  Your withdrawal will not affect 
the care you receive. 
  
What are the possible benefits of taking part in the study? 
 
You will receive more detailed cognitive assessments in addition 
to your routine assessments.  This more detailed assessment may 
allow more accurate detection of cognitive problems.  In addition, 
future stroke patients may benefit as the information may help to 
improve methods of assessing cognitive problems. 
 
What are the possible disadvantages of taking part? 
 
There are no physical or emotional risks in taking part in this 
study.  It is possible that if you are unable to answer all the 
questions you may feel as though you are failing.  This is not the 
case as different people perform differently on all aspects of the 
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test.  At the end of the session there will be a chance to discuss 
your experience and ask any questions. 
 
What if there is a problem? 
 
You can speak to a member of the research team about any 
concerns you have.  If you wish to make a formal complaint about 
any aspect of the way you have been treated during the course of 
this study, you can do this through the NHS Complaints 
Procedure. 
 
Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of 
the research will be kept strictly confidential and any information 
about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised.   
 
What will happen to the results of the study? 
 
They will be presented as a university degree thesis and presented 
for publication in a scientific journal.  Your own scores on the 
tests will not be personally identifiable in any report.  We will 
send you a summary of results of the study when it is finished 
(probably in 2009).   
 
Who is organising this study? 
 
The Stroke Service at Nottingham University Hospitals NHS 
Trust and the University of Lincoln. 
 
Who has reviewed the study? 
 
This study has been reviewed and given favourable opinion by 
…………………………..Research Ethics Committee. 
 
What happens now? 
 
Take time to decide whether you want to take part in the study.  If 
you decide to take part, you will be asked to sign a consent form.   
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Thank you for taking time to read this. 
 
 
Contact information 
 
If you have any questions about this study you may contact: 
 
Dr Vicki Hacker 
Clinical Psychologist  
Nottingham University 
Hospitals NHS Trust 
Beeston Ward 
Hucknall Road 
Nottingham 
NG5 1PB 
0115 9691169 ext.46550 
 
Prof. Nadina Lincoln 
Research Director 
University of Nottingham 
William Lee Buildings 8 
Science & Technology Park 
Nottingham 
NG7 2RQ 
0115 9515315 
 
Miss Katie Morris  
Trainee Clinical Psychologist 
University of Lincoln 
Health, Life and Social Sciences 
Court 11, Satellite Building 8 
Brayford Pool 
Lincoln 
LN6 7TS 
01522 886029 
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Patient Number: 
 
CONSENT FORM (A) 
 
The validity of the Addenbrooke’s Cognitive  
examination- Revised (ACE-R) in Stroke 
 
Investigators:  Dr Vicki Hacker, Prof. Nadina Lincoln, Miss Katie Morris 
 
 
1) I have read and understood the information sheet 
(dated 06/08/07, version 1).   
 
 
 
 
 
 
2) My participation is voluntary.  I can withdraw at 
any time, without giving any reason.   
 
 
3) I agree to take part in the above study.   
 
 
4) The researchers can have access to my medical 
records. 
 
 
 
Name of Patient   Date   Signature 
 
 
 
 
Name of Person    Date   Signature 
taking consent    
 
 
 
 
 
 
 
 
1 copy for patient, 1 for research file; 1 (original) to be kept in medical notes). 
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Patient Number: 
 
CONSENT FORM (B) 
 
The validity of the Addenbrooke’s Cognitive  
examination- Revised (ACE-R) in Stroke 
 
Investigators:  Dr Vicki Hacker, Prof. Nadina Lincoln, Miss Katie Morris 
 
 
5) I have read and understood the information sheet 
(dated 06/08/07, version 1).   
 
 
 
 
 
6) My participation is voluntary.  I can withdraw at 
any time, without giving any reason.   
 
 
7) I agree to take part in the above study.   
 
 
 8) The researchers can have access to my medical 
records. 
 
 
5) I would/ would not like the results of my assessments to        
be passed to the medical team (please delete as appropriate). 
 
    
Name of Patient   Date   Signature 
 
 
 
 
Name of Person    Date   Signature 
taking consent    
 
 
 
 
1 copy for patient, 1 for research file; 1 (original) to be kept in medical notes). 
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Appendix 5 
The ACE-R  
(Mioshi et al., 2006)
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